Level/ Type |
Code |
Display Name |
Code System |
Description |
0-L |
A |
ALIMENTARY TRACT AND METABOLISM |
WHO ATC |
|
0-L |
A01 |
STOMATOLOGICAL PREPARATIONS |
WHO ATC |
|
0-L |
A01A |
STOMATOLOGICAL PREPARATIONS |
WHO ATC |
|
0-L |
A01AA |
Caries prophylactic agents |
WHO ATC |
|
0-L |
A01AA01 |
sodium fluoride |
WHO ATC |
|
0-L |
A01AA02 |
sodium monofluorophosphate |
WHO ATC |
|
0-L |
A01AA03 |
olaflur |
WHO ATC |
|
0-L |
A01AA04 |
stannous fluoride |
WHO ATC |
|
0-L |
A01AA30 |
combinations |
WHO ATC |
|
0-L |
A01AA51 |
sodium fluoride, combinations |
WHO ATC |
|
0-L |
A01AB |
Antiinfectives and antiseptics for local oral treatment |
WHO ATC |
|
0-L |
A01AB02 |
hydrogen peroxide |
WHO ATC |
|
0-L |
A01AB03 |
chlorhexidine |
WHO ATC |
|
0-L |
A01AB04 |
amphotericin B |
WHO ATC |
|
0-L |
A01AB05 |
polynoxylin |
WHO ATC |
|
0-L |
A01AB06 |
domiphen |
WHO ATC |
|
0-L |
A01AB07 |
oxyquinoline |
WHO ATC |
|
0-L |
A01AB08 |
neomycin |
WHO ATC |
|
0-L |
A01AB09 |
miconazole |
WHO ATC |
|
0-L |
A01AB10 |
natamycin |
WHO ATC |
|
0-L |
A01AB11 |
various |
WHO ATC |
|
0-L |
A01AB12 |
hexetidine |
WHO ATC |
|
0-L |
A01AB13 |
tetracycline |
WHO ATC |
|
0-L |
A01AB14 |
benzoxonium chloride |
WHO ATC |
|
0-L |
A01AB15 |
tibezonium iodide |
WHO ATC |
|
0-L |
A01AB16 |
mepartricin |
WHO ATC |
|
0-L |
A01AB17 |
metronidazole |
WHO ATC |
|
0-L |
A01AB18 |
clotrimazole |
WHO ATC |
|
0-L |
A01AB19 |
sodium perborate |
WHO ATC |
|
0-L |
A01AB21 |
chlortetracycline |
WHO ATC |
|
0-L |
A01AB22 |
doxycycline |
WHO ATC |
|
0-L |
A01AB23 |
minocycline |
WHO ATC |
|
0-L |
A01AC |
Corticosteroids for local oral treatment |
WHO ATC |
|
0-L |
A01AC01 |
triamcinolone |
WHO ATC |
|
0-L |
A01AC02 |
dexamethasone |
WHO ATC |
|
0-L |
A01AC03 |
hydrocortisone |
WHO ATC |
|
0-L |
A01AC54 |
prednisolone, combinations |
WHO ATC |
|
0-L |
A01AD |
Other agents for local oral treatment |
WHO ATC |
|
0-L |
A01AD01 |
epinephrine |
WHO ATC |
|
0-L |
A01AD02 |
benzydamine |
WHO ATC |
|
0-L |
A01AD05 |
acetylsalicylic acid |
WHO ATC |
|
0-L |
A01AD06 |
adrenalone |
WHO ATC |
|
0-L |
A01AD07 |
amlexanox |
WHO ATC |
|
0-L |
A01AD08 |
becaplermin |
WHO ATC |
|
0-L |
A01AD11 |
various |
WHO ATC |
|
0-L |
A02 |
DRUGS FOR ACID RELATED DISORDERS |
WHO ATC |
|
0-L |
A02A |
ANTACIDS |
WHO ATC |
|
0-L |
A02AA |
Magnesium compounds |
WHO ATC |
|
0-L |
A02AA01 |
magnesium carbonate |
WHO ATC |
|
0-L |
A02AA02 |
magnesium oxide |
WHO ATC |
|
0-L |
A02AA03 |
magnesium peroxide |
WHO ATC |
|
0-L |
A02AA04 |
magnesium hydroxide |
WHO ATC |
|
0-L |
A02AA05 |
magnesium silicate |
WHO ATC |
|
0-L |
A02AA10 |
combinations |
WHO ATC |
|
0-L |
A02AB |
Aluminium compounds |
WHO ATC |
|
0-L |
A02AB01 |
aluminium hydroxide |
WHO ATC |
|
0-L |
A02AB02 |
algeldrate |
WHO ATC |
|
0-L |
A02AB03 |
aluminium phosphate |
WHO ATC |
|
0-L |
A02AB04 |
dihydroxialumini sodium carbonate |
WHO ATC |
|
0-L |
A02AB05 |
aluminium acetoacetate |
WHO ATC |
|
0-L |
A02AB06 |
aloglutamol |
WHO ATC |
|
0-L |
A02AB07 |
aluminium glycinate |
WHO ATC |
|
0-L |
A02AB10 |
combinations |
WHO ATC |
|
0-L |
A02AC |
Calcium compounds |
WHO ATC |
|
0-L |
A02AC01 |
calcium carbonate |
WHO ATC |
|
0-L |
A02AC02 |
calcium silicate |
WHO ATC |
|
0-L |
A02AC10 |
combinations |
WHO ATC |
|
0-L |
A02AD |
Combinations and complexes of aluminium, calcium and magnesium compounds |
WHO ATC |
|
0-L |
A02AD01 |
ordinary salt combinations |
WHO ATC |
|
0-L |
A02AD02 |
magaldrate |
WHO ATC |
|
0-L |
A02AD03 |
almagate |
WHO ATC |
|
0-L |
A02AD04 |
hydrotalcite |
WHO ATC |
|
0-L |
A02AD05 |
almasilate |
WHO ATC |
|
0-L |
A02AF |
Antacids with antiflatulents |
WHO ATC |
|
0-L |
A02AF01 |
magaldrate and antiflatulents |
WHO ATC |
|
0-L |
A02AF02 |
ordinary salt combinations and antiflatulents |
WHO ATC |
|
0-L |
A02AG |
Antacids with antispasmodics |
WHO ATC |
|
0-L |
A02AH |
Antacids with sodium bicarbonate |
WHO ATC |
|
0-L |
A02AX |
Antacids, other combinations |
WHO ATC |
|
0-L |
A02B |
DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD) |
WHO ATC |
|
0-L |
A02BA |
H2-receptor antagonists |
WHO ATC |
|
0-L |
A02BA01 |
cimetidine |
WHO ATC |
|
0-L |
A02BA02 |
ranitidine |
WHO ATC |
|
0-L |
A02BA03 |
famotidine |
WHO ATC |
|
0-L |
A02BA04 |
nizatidine |
WHO ATC |
|
0-L |
A02BA05 |
niperotidine |
WHO ATC |
|
0-L |
A02BA06 |
roxatidine |
WHO ATC |
|
0-L |
A02BA07 |
ranitidine bismuth citrate |
WHO ATC |
|
0-L |
A02BA08 |
lafutidine |
WHO ATC |
|
0-L |
A02BA51 |
cimetidine, combinations |
WHO ATC |
|
0-L |
A02BA53 |
famotidine, combinations |
WHO ATC |
|
0-L |
A02BB |
Prostaglandins |
WHO ATC |
|
0-L |
A02BB01 |
misoprostol |
WHO ATC |
|
0-L |
A02BB02 |
enprostil |
WHO ATC |
|
0-L |
A02BC |
Proton pump inhibitors |
WHO ATC |
|
0-L |
A02BC01 |
omeprazole |
WHO ATC |
|
0-L |
A02BC02 |
pantoprazole |
WHO ATC |
|
0-L |
A02BC03 |
lansoprazole |
WHO ATC |
|
0-L |
A02BC04 |
rabeprazole |
WHO ATC |
|
0-L |
A02BC05 |
esomeprazole |
WHO ATC |
|
0-L |
A02BD |
Combinations for eradication of Helicobacter pylori |
WHO ATC |
|
0-L |
A02BD01 |
omeprazole, amoxicillin and metronidazole |
WHO ATC |
|
0-L |
A02BD02 |
lansoprazole, tetracycline and metronidazole |
WHO ATC |
|
0-L |
A02BD03 |
lansoprazole, amoxicillin and metronidazole |
WHO ATC |
|
0-L |
A02BD04 |
pantoprazole, amoxicillin and clarithromycin |
WHO ATC |
|
0-L |
A02BD05 |
omeprazole, amoxicillin and clarithromycin |
WHO ATC |
|
0-L |
A02BD06 |
esomeprazole, amoxicillin and clarithromycin |
WHO ATC |
|
0-L |
A02BD07 |
lansoprazole, amoxicillin and clarithromycin |
WHO ATC |
|
0-L |
A02BX |
Other drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) |
WHO ATC |
|
0-L |
A02BX01 |
carbenoxolone |
WHO ATC |
|
0-L |
A02BX02 |
sucralfate |
WHO ATC |
|
0-L |
A02BX03 |
pirenzepine |
WHO ATC |
|
0-L |
A02BX04 |
methiosulfonium chloride |
WHO ATC |
|
0-L |
A02BX05 |
bismuth subcitrate |
WHO ATC |
|
0-L |
A02BX06 |
proglumide |
WHO ATC |
|
0-L |
A02BX07 |
gefarnate |
WHO ATC |
|
0-L |
A02BX08 |
sulglicotide |
WHO ATC |
|
0-L |
A02BX09 |
acetoxolone |
WHO ATC |
|
0-L |
A02BX10 |
zolimidine |
WHO ATC |
|
0-L |
A02BX11 |
troxipide |
WHO ATC |
|
0-L |
A02BX12 |
bismuth subnitrate |
WHO ATC |
|
0-L |
A02BX13 |
alginic acid |
WHO ATC |
|
0-L |
A02BX51 |
carbenoxolone, combinations excl. psycholeptics |
WHO ATC |
|
0-L |
A02BX71 |
carbenoxolone, combinations with psycholeptics |
WHO ATC |
|
0-L |
A02BX77 |
gefarnate, combinations with psycholeptics |
WHO ATC |
|
0-L |
A02X |
OTHER DRUGS FOR ACID RELATED DISORDERS |
WHO ATC |
|
0-L |
A03 |
DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS |
WHO ATC |
|
0-L |
A03A |
DRUGS FOR FUNCTIONAL BOWEL DISORDERS |
WHO ATC |
|
0-L |
A03AA |
Synthetic anticholinergics, esters with tertiary amino group |
WHO ATC |
|
0-L |
A03AA01 |
oxyphencyclimine |
WHO ATC |
|
0-L |
A03AA03 |
camylofin |
WHO ATC |
|
0-L |
A03AA04 |
mebeverine |
WHO ATC |
|
0-L |
A03AA05 |
trimebutine |
WHO ATC |
|
0-L |
A03AA06 |
rociverine |
WHO ATC |
|
0-L |
A03AA07 |
dicycloverine |
WHO ATC |
|
0-L |
A03AA08 |
dihexyverine |
WHO ATC |
|
0-L |
A03AA09 |
difemerine |
WHO ATC |
|
0-L |
A03AA30 |
piperidolate |
WHO ATC |
|
0-L |
A03AB |
Synthetic anticholinergics, quaternary ammonium compounds |
WHO ATC |
|
0-L |
A03AB01 |
benzilone |
WHO ATC |
|
0-L |
A03AB02 |
glycopyrronium |
WHO ATC |
|
0-L |
A03AB03 |
oxyphenonium |
WHO ATC |
|
0-L |
A03AB04 |
penthienate |
WHO ATC |
|
0-L |
A03AB05 |
propantheline |
WHO ATC |
|
0-L |
A03AB06 |
otilonium bromide |
WHO ATC |
|
0-L |
A03AB07 |
methantheline |
WHO ATC |
|
0-L |
A03AB08 |
tridihexethyl |
WHO ATC |
|
0-L |
A03AB09 |
isopropamide |
WHO ATC |
|
0-L |
A03AB10 |
hexocyclium |
WHO ATC |
|
0-L |
A03AB11 |
poldine |
WHO ATC |
|
0-L |
A03AB12 |
mepenzolate |
WHO ATC |
|
0-L |
A03AB13 |
bevonium |
WHO ATC |
|
0-L |
A03AB14 |
pipenzolate |
WHO ATC |
|
0-L |
A03AB15 |
diphemanil |
WHO ATC |
|
0-L |
A03AB16 |
(2-benzhydryloxyethyl)diethyl-methylammonium iodide |
WHO ATC |
|
0-L |
A03AB17 |
tiemonium iodide |
WHO ATC |
|
0-L |
A03AB18 |
prifinium bromide |
WHO ATC |
|
0-L |
A03AB19 |
timepidium bromide |
WHO ATC |
|
0-L |
A03AB21 |
fenpiverinium |
WHO ATC |
|
0-L |
A03AB53 |
oxyphenonium, combinations |
WHO ATC |
|
0-L |
A03AC |
Synthetic antispasmodics, amides with tertiary amines |
WHO ATC |
|
0-L |
A03AC02 |
dimethylaminopropionylphenothiazine |
WHO ATC |
|
0-L |
A03AC04 |
nicofetamide |
WHO ATC |
|
0-L |
A03AC05 |
tiropramide |
WHO ATC |
|
0-L |
A03AD |
Papaverine and derivatives |
WHO ATC |
|
0-L |
A03AD01 |
papaverine |
WHO ATC |
|
0-L |
A03AD02 |
drotaverine |
WHO ATC |
|
0-L |
A03AD30 |
moxaverine |
WHO ATC |
|
0-L |
A03AE |
Drugs acting on serotonin receptors |
WHO ATC |
|
0-L |
A03AE01 |
alosetron |
WHO ATC |
|
0-L |
A03AE02 |
tegaserod |
WHO ATC |
|
0-L |
A03AE03 |
cilansetron |
WHO ATC |
|
0-L |
A03AE04 |
prucalopride |
WHO ATC |
|
0-L |
A03AX |
Other drugs for functional bowel disorders |
WHO ATC |
|
0-L |
A03AX01 |
fenpiprane |
WHO ATC |
|
0-L |
A03AX02 |
diisopromine |
WHO ATC |
|
0-L |
A03AX03 |
chlorbenzoxamine |
WHO ATC |
|
0-L |
A03AX04 |
pinaverium |
WHO ATC |
|
0-L |
A03AX05 |
fenoverine |
WHO ATC |
|
0-L |
A03AX06 |
idanpramine |
WHO ATC |
|
0-L |
A03AX07 |
proxazole |
WHO ATC |
|
0-L |
A03AX08 |
alverine |
WHO ATC |
|
0-L |
A03AX09 |
trepibutone |
WHO ATC |
|
0-L |
A03AX10 |
isometheptene |
WHO ATC |
|
0-L |
A03AX11 |
caroverine |
WHO ATC |
|
0-L |
A03AX12 |
phloroglucinol |
WHO ATC |
|
0-L |
A03AX13 |
silicones |
WHO ATC |
|
0-L |
A03AX30 |
trimethyldiphenylpropylamine |
WHO ATC |
|
0-L |
A03AX58 |
alverine, combinations |
WHO ATC |
|
0-L |
A03B |
BELLADONNA AND DERIVATIVES, PLAIN |
WHO ATC |
|
0-L |
A03BA |
Belladonna alkaloids, tertiary amines |
WHO ATC |
|
0-L |
A03BA01 |
atropine |
WHO ATC |
|
0-L |
A03BA03 |
hyoscyamine |
WHO ATC |
|
0-L |
A03BA04 |
belladonna total alkaloids |
WHO ATC |
|
0-L |
A03BB |
Belladonna alkaloids, semisynthetic, quaternary ammonium compounds |
WHO ATC |
|
0-L |
A03BB01 |
butylscopolamine |
WHO ATC |
|
0-L |
A03BB02 |
methylatropine |
WHO ATC |
|
0-L |
A03BB03 |
methylscopolamine |
WHO ATC |
|
0-L |
A03BB04 |
fentonium |
WHO ATC |
|
0-L |
A03BB05 |
cimetropium bromide |
WHO ATC |
|
0-L |
A03C |
ANTISPASMODICS IN COMBINATION WITH PSYCHOLEPTICS |
WHO ATC |
|
0-L |
A03CA |
Synthetic anticholinergic agents in combination with psycholeptics |
WHO ATC |
|
0-L |
A03CA01 |
isopropamide and psycholeptics |
WHO ATC |
|
0-L |
A03CA02 |
clidinium and psycholeptics |
WHO ATC |
|
0-L |
A03CA03 |
oxyphencyclimine and psycholeptics |
WHO ATC |
|
0-L |
A03CA04 |
otilonium bromide and psycholeptics |
WHO ATC |
|
0-L |
A03CA05 |
glycopyrronium and psycholeptics |
WHO ATC |
|
0-L |
A03CA06 |
bevonium and psycholeptics |
WHO ATC |
|
0-L |
A03CA07 |
ambutonium and psycholeptics |
WHO ATC |
|
0-L |
A03CA08 |
diphemanil and psycholeptics |
WHO ATC |
|
0-L |
A03CA30 |
emepronium and psycholeptics |
WHO ATC |
|
0-L |
A03CA34 |
propantheline and psycholeptics |
WHO ATC |
|
0-L |
A03CB |
Belladonna and derivatives in combination with psycholeptics |
WHO ATC |
|
0-L |
A03CB01 |
methylscopolamine and psycholeptics |
WHO ATC |
|
0-L |
A03CB02 |
belladonna total alkaloids and psycholeptics |
WHO ATC |
|
0-L |
A03CB03 |
atropine and psycholeptics |
WHO ATC |
|
0-L |
A03CB04 |
methylhomatropine and psycholeptics |
WHO ATC |
|
0-L |
A03CB31 |
hyoscyamine and psycholeptics |
WHO ATC |
|
0-L |
A03CC |
Other antispasmodics in combination with psycholeptics |
WHO ATC |
|
0-L |
A03D |
ANTISPASMODICS IN COMBINATION WITH ANALGESICS |
WHO ATC |
|
0-L |
A03DA |
Synthetic anticholinergic agents in combination with analgesics |
WHO ATC |
|
0-L |
A03DA01 |
tropenzilone and analgesics |
WHO ATC |
|
0-L |
A03DA02 |
pitofenone and analgesics |
WHO ATC |
|
0-L |
A03DA03 |
bevonium and analgesics |
WHO ATC |
|
0-L |
A03DA04 |
ciclonium and analgesics |
WHO ATC |
|
0-L |
A03DA05 |
camylofin and analgesics |
WHO ATC |
|
0-L |
A03DA06 |
trospium and analgesics |
WHO ATC |
|
0-L |
A03DA07 |
tiemonium iodide and analgesics |
WHO ATC |
|
0-L |
A03DB |
Belladonna and derivatives in combination with analgesics |
WHO ATC |
|
0-L |
A03DB04 |
butylscopolamine and analgesics |
WHO ATC |
|
0-L |
A03DC |
Other antispasmodics in combination with analgesics |
WHO ATC |
|
0-L |
A03E |
ANTISPASMODICS AND ANTICHOLINERGICS IN COMBINATION WITH OTHER DRUGS |
WHO ATC |
|
0-L |
A03EA |
Antispasmodics, psycholeptics and analgesics in combination |
WHO ATC |
|
0-L |
A03ED |
Antispasmodics in combination with other drugs |
WHO ATC |
|
0-L |
A03F |
PROPULSIVES |
WHO ATC |
|
0-L |
A03FA |
Propulsives |
WHO ATC |
|
0-L |
A03FA01 |
metoclopramide |
WHO ATC |
|
0-L |
A03FA02 |
cisapride |
WHO ATC |
|
0-L |
A03FA03 |
domperidone |
WHO ATC |
|
0-L |
A03FA04 |
bromopride |
WHO ATC |
|
0-L |
A03FA05 |
alizapride |
WHO ATC |
|
0-L |
A03FA06 |
clebopride |
WHO ATC |
|
0-L |
A04 |
ANTIEMETICS AND ANTINAUSEANTS |
WHO ATC |
|
0-L |
A04A |
ANTIEMETICS AND ANTINAUSEANTS |
WHO ATC |
|
0-L |
A04AA |
Serotonin (5HT3) antagonists |
WHO ATC |
|
0-L |
A04AA01 |
ondansetron |
WHO ATC |
|
0-L |
A04AA02 |
granisetron |
WHO ATC |
|
0-L |
A04AA03 |
tropisetron |
WHO ATC |
|
0-L |
A04AA04 |
dolasetron |
WHO ATC |
|
0-L |
A04AA05 |
palonosetron |
WHO ATC |
|
0-L |
A04AD |
Other antiemetics |
WHO ATC |
|
0-L |
A04AD01 |
scopolamine |
WHO ATC |
|
0-L |
A04AD02 |
cerium oxalate |
WHO ATC |
|
0-L |
A04AD04 |
chlorobutanol |
WHO ATC |
|
0-L |
A04AD05 |
metopimazine |
WHO ATC |
|
0-L |
A04AD10 |
dronabinol |
WHO ATC |
|
0-L |
A04AD11 |
nabilone |
WHO ATC |
|
0-L |
A04AD12 |
aprepitant |
WHO ATC |
|
0-L |
A04AD13 |
casopitant |
WHO ATC |
|
0-L |
A04AD51 |
scopolamine, combinations |
WHO ATC |
|
0-L |
A04AD54 |
chlorobutanol, combinations |
WHO ATC |
|
0-L |
A05 |
BILE AND LIVER THERAPY |
WHO ATC |
|
0-L |
A05A |
BILE THERAPY |
WHO ATC |
|
0-L |
A05AA |
Bile acid preparations |
WHO ATC |
|
0-L |
A05AA01 |
chenodeoxycholic acid |
WHO ATC |
|
0-L |
A05AA02 |
ursodeoxycholic acid |
WHO ATC |
|
0-L |
A05AA03 |
cholic acid |
WHO ATC |
|
0-L |
A05AB |
Preparations for biliary tract therapy |
WHO ATC |
|
0-L |
A05AB01 |
nicotinyl methylamide |
WHO ATC |
|
0-L |
A05AX |
Other drugs for bile therapy |
WHO ATC |
|
0-L |
A05AX01 |
piprozolin |
WHO ATC |
|
0-L |
A05AX02 |
hymecromone |
WHO ATC |
|
0-L |
A05AX03 |
cyclobutyrol |
WHO ATC |
|
0-L |
A05B |
LIVER THERAPY, LIPOTROPICS |
WHO ATC |
|
0-L |
A05BA |
Liver therapy |
WHO ATC |
|
0-L |
A05BA01 |
arginine glutamate |
WHO ATC |
|
0-L |
A05BA03 |
silymarin |
WHO ATC |
|
0-L |
A05BA04 |
citiolone |
WHO ATC |
|
0-L |
A05BA05 |
epomediol |
WHO ATC |
|
0-L |
A05BA06 |
ornithine oxoglurate |
WHO ATC |
|
0-L |
A05BA07 |
tidiacic arginine |
WHO ATC |
|
0-L |
A05BA08 |
glycyrrhizic acid |
WHO ATC |
|
0-L |
A05C |
DRUGS FOR BILE THERAPY AND LIPOTROPICS IN COMBINATION |
WHO ATC |
|
0-L |
A06 |
LAXATIVES |
WHO ATC |
|
0-L |
A06A |
LAXATIVES |
WHO ATC |
|
0-L |
A06AA |
Softeners, emollients |
WHO ATC |
|
0-L |
A06AA01 |
liquid paraffin |
WHO ATC |
|
0-L |
A06AA02 |
docusate sodium |
WHO ATC |
|
0-L |
A06AA51 |
liquid paraffin, combinations |
WHO ATC |
|
0-L |
A06AB |
Contact laxatives |
WHO ATC |
|
0-L |
A06AB01 |
oxyphenisatine |
WHO ATC |
|
0-L |
A06AB02 |
bisacodyl |
WHO ATC |
|
0-L |
A06AB03 |
dantron |
WHO ATC |
|
0-L |
A06AB04 |
phenolphthalein |
WHO ATC |
|
0-L |
A06AB05 |
castor oil |
WHO ATC |
|
0-L |
A06AB06 |
senna glycosides |
WHO ATC |
|
0-L |
A06AB07 |
cascara |
WHO ATC |
|
0-L |
A06AB08 |
sodium picosulfate |
WHO ATC |
|
0-L |
A06AB09 |
bisoxatin |
WHO ATC |
|
0-L |
A06AB20 |
contact laxatives in combination |
WHO ATC |
|
0-L |
A06AB30 |
contact laxatives in combination with belladonna alkaloids |
WHO ATC |
|
0-L |
A06AB52 |
bisacodyl, combinations |
WHO ATC |
|
0-L |
A06AB53 |
dantron, combinations |
WHO ATC |
|
0-L |
A06AB56 |
senna glycosides, combinations |
WHO ATC |
|
0-L |
A06AB57 |
cascara, combinations |
WHO ATC |
|
0-L |
A06AB58 |
sodium picosulfate, combinations |
WHO ATC |
|
0-L |
A06AC |
Bulk producers |
WHO ATC |
|
0-L |
A06AC01 |
ispaghula (psylla seeds) |
WHO ATC |
|
0-L |
A06AC02 |
ethulose |
WHO ATC |
|
0-L |
A06AC03 |
sterculia |
WHO ATC |
|
0-L |
A06AC05 |
linseed |
WHO ATC |
|
0-L |
A06AC06 |
methylcellulose |
WHO ATC |
|
0-L |
A06AC07 |
triticum (wheat fibre) |
WHO ATC |
|
0-L |
A06AC08 |
polycarbophil calcium |
WHO ATC |
|
0-L |
A06AC51 |
ispaghula, combinations |
WHO ATC |
|
0-L |
A06AC53 |
sterculia, combinations |
WHO ATC |
|
0-L |
A06AC55 |
linseed, combinations |
WHO ATC |
|
0-L |
A06AD |
Osmotically acting laxatives |
WHO ATC |
|
0-L |
A06AD01 |
magnesium carbonate |
WHO ATC |
|
0-L |
A06AD02 |
magnesium oxide |
WHO ATC |
|
0-L |
A06AD03 |
magnesium peroxide |
WHO ATC |
|
0-L |
A06AD04 |
magnesium sulfate |
WHO ATC |
|
0-L |
A06AD10 |
mineral salts in combination |
WHO ATC |
|
0-L |
A06AD11 |
lactulose |
WHO ATC |
|
0-L |
A06AD12 |
lactitol |
WHO ATC |
|
0-L |
A06AD13 |
sodium sulfate |
WHO ATC |
|
0-L |
A06AD14 |
pentaerithrityl |
WHO ATC |
|
0-L |
A06AD15 |
macrogol |
WHO ATC |
|
0-L |
A06AD16 |
mannitol |
WHO ATC |
|
0-L |
A06AD17 |
sodium phosphate |
WHO ATC |
|
0-L |
A06AD18 |
sorbitol |
WHO ATC |
|
0-L |
A06AD19 |
magnesium citrate |
WHO ATC |
|
0-L |
A06AD21 |
sodium tartrate |
WHO ATC |
|
0-L |
A06AD61 |
lactulose, combinations |
WHO ATC |
|
0-L |
A06AD65 |
macrogol, combinations |
WHO ATC |
|
0-L |
A06AG |
Enemas |
WHO ATC |
|
0-L |
A06AG01 |
sodium phosphate |
WHO ATC |
|
0-L |
A06AG02 |
bisacodyl |
WHO ATC |
|
0-L |
A06AG03 |
dantron, incl. combinations |
WHO ATC |
|
0-L |
A06AG04 |
glycerol |
WHO ATC |
|
0-L |
A06AG06 |
oil |
WHO ATC |
|
0-L |
A06AG07 |
sorbitol |
WHO ATC |
|
0-L |
A06AG10 |
docusate sodium, incl. combinations |
WHO ATC |
|
0-L |
A06AG11 |
laurilsulfate, incl. combinations |
WHO ATC |
|
0-L |
A06AG20 |
combinations |
WHO ATC |
|
0-L |
A06AH |
Peripheral opioid receptor antagonists |
WHO ATC |
|
0-L |
A06AH01 |
methylnaltrexone bromide |
WHO ATC |
|
0-L |
A06AH02 |
alvimopan |
WHO ATC |
|
0-L |
A06AX |
Other laxatives |
WHO ATC |
|
0-L |
A06AX01 |
glycerol |
WHO ATC |
|
0-L |
A06AX02 |
carbon dioxide producing drugs |
WHO ATC |
|
0-L |
A06AX03 |
lubiprostone |
WHO ATC |
|
0-L |
A07 |
ANTIDIARRHEALS, INTESTINAL ANTIINFLAMMATORY/ANTIINFECTIVEAGENTS |
WHO ATC |
|
0-L |
A07A |
INTESTINAL ANTIINFECTIVES |
WHO ATC |
|
0-L |
A07AA |
Antibiotics |
WHO ATC |
|
0-L |
A07AA01 |
neomycin |
WHO ATC |
|
0-L |
A07AA02 |
nystatin |
WHO ATC |
|
0-L |
A07AA03 |
natamycin |
WHO ATC |
|
0-L |
A07AA04 |
streptomycin |
WHO ATC |
|
0-L |
A07AA05 |
polymyxin B |
WHO ATC |
|
0-L |
A07AA06 |
paromomycin |
WHO ATC |
|
0-L |
A07AA07 |
amphotericin B |
WHO ATC |
|
0-L |
A07AA08 |
kanamycin |
WHO ATC |
|
0-L |
A07AA09 |
vancomycin |
WHO ATC |
|
0-L |
A07AA10 |
colistin |
WHO ATC |
|
0-L |
A07AA11 |
rifaximin |
WHO ATC |
|
0-L |
A07AA51 |
neomycin, combinations |
WHO ATC |
|
0-L |
A07AA54 |
streptomycin, combinations |
WHO ATC |
|
0-L |
A07AB |
Sulfonamides |
WHO ATC |
|
0-L |
A07AB02 |
phthalylsulfathiazole |
WHO ATC |
|
0-L |
A07AB03 |
sulfaguanidine |
WHO ATC |
|
0-L |
A07AB04 |
succinylsulfathiazole |
WHO ATC |
|
0-L |
A07AC |
Imidazole derivatives |
WHO ATC |
|
0-L |
A07AC01 |
miconazole |
WHO ATC |
|
0-L |
A07AX |
Other intestinal antiinfectives |
WHO ATC |
|
0-L |
A07AX01 |
broxyquinoline |
WHO ATC |
|
0-L |
A07AX02 |
acetarsol |
WHO ATC |
|
0-L |
A07AX03 |
nifuroxazide |
WHO ATC |
|
0-L |
A07AX04 |
nifurzide |
WHO ATC |
|
0-L |
A07B |
INTESTINAL ADSORBENTS |
WHO ATC |
|
0-L |
A07BA |
Charcoal preparations |
WHO ATC |
|
0-L |
A07BA01 |
medicinal charcoal |
WHO ATC |
|
0-L |
A07BA51 |
medicinal charcoal, combinations |
WHO ATC |
|
0-L |
A07BB |
Bismuth preparations |
WHO ATC |
|
0-L |
A07BC |
Other intestinal adsorbents |
WHO ATC |
|
0-L |
A07BC01 |
pectin |
WHO ATC |
|
0-L |
A07BC02 |
kaolin |
WHO ATC |
|
0-L |
A07BC03 |
crospovidone |
WHO ATC |
|
0-L |
A07BC04 |
attapulgite |
WHO ATC |
|
0-L |
A07BC05 |
diosmectite |
WHO ATC |
|
0-L |
A07BC30 |
combinations |
WHO ATC |
|
0-L |
A07BC54 |
attapulgite, combinations |
WHO ATC |
|
0-L |
A07C |
ELECTROLYTES WITH CARBOHYDRATES |
WHO ATC |
|
0-L |
A07CA |
Oral rehydration salt formulations |
WHO ATC |
|
0-L |
A07D |
ANTIPROPULSIVES |
WHO ATC |
|
0-L |
A07DA |
Antipropulsives |
WHO ATC |
|
0-L |
A07DA01 |
diphenoxylate |
WHO ATC |
|
0-L |
A07DA02 |
opium |
WHO ATC |
|
0-L |
A07DA03 |
loperamide |
WHO ATC |
|
0-L |
A07DA04 |
difenoxin |
WHO ATC |
|
0-L |
A07DA05 |
loperamide oxide |
WHO ATC |
|
0-L |
A07DA52 |
morphine, combinations |
WHO ATC |
|
0-L |
A07DA53 |
loperamide, combinations |
WHO ATC |
|
0-L |
A07E |
INTESTINAL ANTIINFLAMMATORY AGENTS |
WHO ATC |
|
0-L |
A07EA |
Corticosteroids acting locally |
WHO ATC |
|
0-L |
A07EA01 |
prednisolone |
WHO ATC |
|
0-L |
A07EA02 |
hydrocortisone |
WHO ATC |
|
0-L |
A07EA03 |
prednisone |
WHO ATC |
|
0-L |
A07EA04 |
betamethasone |
WHO ATC |
|
0-L |
A07EA05 |
tixocortol |
WHO ATC |
|
0-L |
A07EA06 |
budesonide |
WHO ATC |
|
0-L |
A07EA07 |
beclometasone |
WHO ATC |
|
0-L |
A07EB |
Antiallergic agents, excl. corticosteroids |
WHO ATC |
|
0-L |
A07EB01 |
cromoglicic acid |
WHO ATC |
|
0-L |
A07EC |
Aminosalicylic acid and similar agents |
WHO ATC |
|
0-L |
A07EC01 |
sulfasalazine |
WHO ATC |
|
0-L |
A07EC02 |
mesalazine |
WHO ATC |
|
0-L |
A07EC03 |
olsalazine |
WHO ATC |
|
0-L |
A07EC04 |
balsalazide |
WHO ATC |
|
0-L |
A07F |
ANTIDIARRHEAL MICROORGANISMS |
WHO ATC |
|
0-L |
A07FA |
Antidiarrheal microorganisms |
WHO ATC |
|
0-L |
A07FA01 |
lactic acid producing organisms |
WHO ATC |
|
0-L |
A07FA02 |
saccharomyces boulardii |
WHO ATC |
|
0-L |
A07FA51 |
lactic acid producing organisms, combinations |
WHO ATC |
|
0-L |
A07X |
OTHER ANTIDIARRHEALS |
WHO ATC |
|
0-L |
A07XA |
Other antidiarrheals |
WHO ATC |
|
0-L |
A07XA01 |
albumin tannate |
WHO ATC |
|
0-L |
A07XA02 |
ceratonia |
WHO ATC |
|
0-L |
A07XA03 |
calcium compounds |
WHO ATC |
|
0-L |
A07XA04 |
racecadotril |
WHO ATC |
|
0-L |
A07XA51 |
albumin tannate, combinations |
WHO ATC |
|
0-L |
A08 |
ANTIOBESITY PREPARATIONS, EXCL. DIET PRODUCTS |
WHO ATC |
|
0-L |
A08A |
ANTIOBESITY PREPARATIONS, EXCL. DIET PRODUCTS |
WHO ATC |
|
0-L |
A08AA |
Centrally acting antiobesity products |
WHO ATC |
|
0-L |
A08AA01 |
phentermine |
WHO ATC |
|
0-L |
A08AA02 |
fenfluramine |
WHO ATC |
|
0-L |
A08AA03 |
amfepramone |
WHO ATC |
|
0-L |
A08AA04 |
dexfenfluramine |
WHO ATC |
|
0-L |
A08AA05 |
mazindol |
WHO ATC |
|
0-L |
A08AA06 |
etilamfetamine |
WHO ATC |
|
0-L |
A08AA07 |
cathine |
WHO ATC |
|
0-L |
A08AA08 |
clobenzorex |
WHO ATC |
|
0-L |
A08AA09 |
mefenorex |
WHO ATC |
|
0-L |
A08AA10 |
sibutramine |
WHO ATC |
|
0-L |
A08AA56 |
ephedrine, combinations |
WHO ATC |
|
0-L |
A08AB |
Peripherally acting antiobesity products |
WHO ATC |
|
0-L |
A08AB01 |
orlistat |
WHO ATC |
|
0-L |
A08AX |
Other antiobesity drugs |
WHO ATC |
|
0-L |
A08AX01 |
rimonabant |
WHO ATC |
|
0-L |
A09 |
DIGESTIVES, INCL. ENZYMES |
WHO ATC |
|
0-L |
A09A |
DIGESTIVES, INCL. ENZYMES |
WHO ATC |
|
0-L |
A09AA |
Enzyme preparations |
WHO ATC |
|
0-L |
A09AA01 |
diastase |
WHO ATC |
|
0-L |
A09AA02 |
multienzymes (lipase, protease etc.) |
WHO ATC |
|
0-L |
A09AA03 |
pepsin |
WHO ATC |
|
0-L |
A09AA04 |
tilactase |
WHO ATC |
|
0-L |
A09AB |
Acid preparations |
WHO ATC |
|
0-L |
A09AB01 |
glutamic acid hydrochloride |
WHO ATC |
|
0-L |
A09AB02 |
betaine hydrochloride |
WHO ATC |
|
0-L |
A09AB03 |
hydrochloric acid |
WHO ATC |
|
0-L |
A09AB04 |
citric acid |
WHO ATC |
|
0-L |
A09AC |
Enzyme and acid preparations, combinations |
WHO ATC |
|
0-L |
A09AC01 |
pepsin and acid preparations |
WHO ATC |
|
0-L |
A09AC02 |
multienzymes and acid preparations |
WHO ATC |
|
0-L |
A10 |
DRUGS USED IN DIABETES |
WHO ATC |
|
0-L |
A10A |
INSULINS AND ANALOGUES |
WHO ATC |
|
0-L |
A10AB |
Insulins and analogues for injection, fast-acting |
WHO ATC |
|
0-L |
A10AB01 |
insulin (human) |
WHO ATC |
|
0-L |
A10AB02 |
insulin (beef) |
WHO ATC |
|
0-L |
A10AB03 |
insulin (pork) |
WHO ATC |
|
0-L |
A10AB04 |
insulin lispro |
WHO ATC |
|
0-L |
A10AB05 |
insulin aspart |
WHO ATC |
|
0-L |
A10AB06 |
insulin glulisine |
WHO ATC |
|
0-L |
A10AB30 |
combinations |
WHO ATC |
|
0-L |
A10AC |
Insulins and analogues for injection, intermediate-acting |
WHO ATC |
|
0-L |
A10AC01 |
insulin (human) |
WHO ATC |
|
0-L |
A10AC02 |
insulin (beef) |
WHO ATC |
|
0-L |
A10AC03 |
insulin (pork) |
WHO ATC |
|
0-L |
A10AC04 |
insulin lispro |
WHO ATC |
|
0-L |
A10AC30 |
combinations |
WHO ATC |
|
0-L |
A10AD |
Insulins and analogues for injection, intermediate-acting combined with fast-acting |
WHO ATC |
|
0-L |
A10AD01 |
insulin (human) |
WHO ATC |
|
0-L |
A10AD02 |
insulin (beef) |
WHO ATC |
|
0-L |
A10AD03 |
insulin (pork) |
WHO ATC |
|
0-L |
A10AD04 |
Insulin lispro |
WHO ATC |
|
0-L |
A10AD05 |
insulin aspart |
WHO ATC |
|
0-L |
A10AD30 |
combinations |
WHO ATC |
|
0-L |
A10AE |
Insulins and analogues for injection, long-acting |
WHO ATC |
|
0-L |
A10AE01 |
insulin (human) |
WHO ATC |
|
0-L |
A10AE02 |
insulin (beef) |
WHO ATC |
|
0-L |
A10AE03 |
insulin (pork) |
WHO ATC |
|
0-L |
A10AE04 |
insulin glargine |
WHO ATC |
|
0-L |
A10AE05 |
insulin detemir |
WHO ATC |
|
0-L |
A10AE30 |
combinations |
WHO ATC |
|
0-L |
A10AF |
Insulins and analogues for inhalation |
WHO ATC |
|
0-L |
A10AF01 |
insulin (human) |
WHO ATC |
|
0-L |
A10B |
BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS |
WHO ATC |
|
0-L |
A10BA |
Biguanides |
WHO ATC |
|
0-L |
A10BA01 |
phenformin |
WHO ATC |
|
0-L |
A10BA02 |
metformin |
WHO ATC |
|
0-L |
A10BA03 |
buformin |
WHO ATC |
|
0-L |
A10BB |
Sulfonamides, urea derivatives |
WHO ATC |
|
0-L |
A10BB01 |
glibenclamide |
WHO ATC |
|
0-L |
A10BB02 |
chlorpropamide |
WHO ATC |
|
0-L |
A10BB03 |
tolbutamide |
WHO ATC |
|
0-L |
A10BB04 |
glibornuride |
WHO ATC |
|
0-L |
A10BB05 |
tolazamide |
WHO ATC |
|
0-L |
A10BB06 |
carbutamide |
WHO ATC |
|
0-L |
A10BB07 |
glipizide |
WHO ATC |
|
0-L |
A10BB08 |
gliquidone |
WHO ATC |
|
0-L |
A10BB09 |
gliclazide |
WHO ATC |
|
0-L |
A10BB10 |
metahexamide |
WHO ATC |
|
0-L |
A10BB11 |
glisoxepide |
WHO ATC |
|
0-L |
A10BB12 |
glimepiride |
WHO ATC |
|
0-L |
A10BB31 |
acetohexamide |
WHO ATC |
|
0-L |
A10BC |
Sulfonamides (heterocyclic) |
WHO ATC |
|
0-L |
A10BC01 |
glymidine |
WHO ATC |
|
0-L |
A10BD |
Combinations of oral blood glucose lowering drugs |
WHO ATC |
|
0-L |
A10BD01 |
phenformin and sulfonamides |
WHO ATC |
|
0-L |
A10BD02 |
metformin and sulfonamides |
WHO ATC |
|
0-L |
A10BD03 |
metformin and rosiglitazone |
WHO ATC |
|
0-L |
A10BD04 |
glimepiride and rosiglitazone |
WHO ATC |
|
0-L |
A10BD05 |
metformin and pioglitazone |
WHO ATC |
|
0-L |
A10BD06 |
glimepiride and pioglitazone |
WHO ATC |
|
0-L |
A10BD07 |
metformin and sitagliptin |
WHO ATC |
|
0-L |
A10BD08 |
metformin and vildagliptin |
WHO ATC |
|
0-L |
A10BD09 |
pioglitazone and alogliptin |
WHO ATC |
|
0-L |
A10BF |
Alpha glucosidase inhibitors |
WHO ATC |
|
0-L |
A10BF01 |
acarbose |
WHO ATC |
|
0-L |
A10BF02 |
miglitol |
WHO ATC |
|
0-L |
A10BF03 |
voglibose |
WHO ATC |
|
0-L |
A10BG |
Thiazolidinediones |
WHO ATC |
|
0-L |
A10BG01 |
troglitazone |
WHO ATC |
|
0-L |
A10BG02 |
rosiglitazone |
WHO ATC |
|
0-L |
A10BG03 |
pioglitazone |
WHO ATC |
|
0-L |
A10BH |
Dipeptidyl peptidase 4 (DPP-4) inhibitors |
WHO ATC |
|
0-L |
A10BH01 |
sitagliptin |
WHO ATC |
|
0-L |
A10BH02 |
vildagliptin |
WHO ATC |
|
0-L |
A10BH03 |
saxagliptin |
WHO ATC |
|
0-L |
A10BH04 |
alogliptin |
WHO ATC |
|
0-L |
A10BX |
Other blood glucose lowering drugs, excl. insulins |
WHO ATC |
|
0-L |
A10BX01 |
guar gum |
WHO ATC |
|
0-L |
A10BX02 |
repaglinide |
WHO ATC |
|
0-L |
A10BX03 |
nateglinide |
WHO ATC |
|
0-L |
A10BX04 |
exenatide |
WHO ATC |
|
0-L |
A10BX05 |
pramlintide |
WHO ATC |
|
0-L |
A10BX06 |
benfluorex |
WHO ATC |
|
0-L |
A10BX07 |
liraglutide |
WHO ATC |
|
0-L |
A10BX08 |
mitiglinide |
WHO ATC |
|
0-L |
A10X |
OTHER DRUGS USED IN DIABETES |
WHO ATC |
|
0-L |
A10XA |
Aldose reductase inhibitors |
WHO ATC |
|
0-L |
A10XA01 |
tolrestat |
WHO ATC |
|
0-L |
A11 |
VITAMINS |
WHO ATC |
|
0-L |
A11A |
MULTIVITAMINS, COMBINATIONS |
WHO ATC |
|
0-L |
A11AA |
Multivitamins with minerals |
WHO ATC |
|
0-L |
A11AA01 |
multivitamins and iron |
WHO ATC |
|
0-L |
A11AA02 |
multivitamins and calcium |
WHO ATC |
|
0-L |
A11AA03 |
multivitamins and other minerals, incl. combinations |
WHO ATC |
|
0-L |
A11AA04 |
multivitamins and trace elements |
WHO ATC |
|
0-L |
A11AB |
Multivitamins, other combinations |
WHO ATC |
|
0-L |
A11B |
MULTIVITAMINS, PLAIN |
WHO ATC |
|
0-L |
A11BA |
Multivitamins, plain |
WHO ATC |
|
0-L |
A11C |
VITAMIN A AND D, INCL. COMBINATIONS OF THE TWO |
WHO ATC |
|
0-L |
A11CA |
Vitamin A, plain |
WHO ATC |
|
0-L |
A11CA01 |
retinol (vit A) |
WHO ATC |
|
0-L |
A11CA02 |
betacarotene |
WHO ATC |
|
0-L |
A11CB |
Vitamin A and D in combination |
WHO ATC |
|
0-L |
A11CC |
Vitamin D and analogues |
WHO ATC |
|
0-L |
A11CC01 |
ergocalciferol |
WHO ATC |
|
0-L |
A11CC02 |
dihydrotachysterol |
WHO ATC |
|
0-L |
A11CC03 |
alfacalcidol |
WHO ATC |
|
0-L |
A11CC04 |
calcitriol |
WHO ATC |
|
0-L |
A11CC05 |
colecalciferol |
WHO ATC |
|
0-L |
A11CC06 |
calcifediol |
WHO ATC |
|
0-L |
A11CC20 |
combinations |
WHO ATC |
|
0-L |
A11D |
VITAMIN B1, PLAIN AND IN COMBINATION WITH VITAMIN B6 AND B12 |
WHO ATC |
|
0-L |
A11DA |
Vitamin B1, plain |
WHO ATC |
|
0-L |
A11DA01 |
thiamine (vit B1) |
WHO ATC |
|
0-L |
A11DA02 |
sulbutiamine |
WHO ATC |
|
0-L |
A11DA03 |
benfotiamine |
WHO ATC |
|
0-L |
A11DB |
Vitamin B1 in combination with vitamin B6 and/or vitamin B12 |
WHO ATC |
|
0-L |
A11E |
VITAMIN B-COMPLEX, INCL. COMBINATIONS |
WHO ATC |
|
0-L |
A11EA |
Vitamin B-complex, plain |
WHO ATC |
|
0-L |
A11EB |
Vitamin B-complex with vitamin C |
WHO ATC |
|
0-L |
A11EC |
Vitamin B-complex with minerals |
WHO ATC |
|
0-L |
A11ED |
Vitamin B-complex with anabolic steroids |
WHO ATC |
|
0-L |
A11EX |
Vitamin B-complex, other combinations |
WHO ATC |
|
0-L |
A11G |
ASCORBIC ACID (VITAMIN C), INCL. COMBINATIONS |
WHO ATC |
|
0-L |
A11GA |
Ascorbic acid (vitamin C), plain |
WHO ATC |
|
0-L |
A11GA01 |
ascorbic acid (vit C) |
WHO ATC |
|
0-L |
A11GB |
Ascorbic acid (vitamin C), combinations |
WHO ATC |
|
0-L |
A11GB01 |
ascorbic acid (vit C) and calcium |
WHO ATC |
|
0-L |
A11H |
OTHER PLAIN VITAMIN PREPARATIONS |
WHO ATC |
|
0-L |
A11HA |
Other plain vitamin preparations |
WHO ATC |
|
0-L |
A11HA01 |
nicotinamide |
WHO ATC |
|
0-L |
A11HA02 |
pyridoxine (vit B6) |
WHO ATC |
|
0-L |
A11HA03 |
tocopherol (vit E) |
WHO ATC |
|
0-L |
A11HA04 |
riboflavin (vit B2) |
WHO ATC |
|
0-L |
A11HA05 |
biotin |
WHO ATC |
|
0-L |
A11HA06 |
pyridoxal phosphate |
WHO ATC |
|
0-L |
A11HA07 |
inositol |
WHO ATC |
|
0-L |
A11HA08 |
tocofersolan |
WHO ATC |
|
0-L |
A11HA30 |
dexpanthenol |
WHO ATC |
|
0-L |
A11HA31 |
calcium pantothenate |
WHO ATC |
|
0-L |
A11HA32 |
pantethine |
WHO ATC |
|
0-L |
A11J |
OTHER VITAMIN PRODUCTS, COMBINATIONS |
WHO ATC |
|
0-L |
A11JA |
Combinations of vitamins |
WHO ATC |
|
0-L |
A11JB |
Vitamins with minerals |
WHO ATC |
|
0-L |
A11JC |
Vitamins, other combinations |
WHO ATC |
|
0-L |
A12 |
MINERAL SUPPLEMENTS |
WHO ATC |
|
0-L |
A12A |
CALCIUM |
WHO ATC |
|
0-L |
A12AA |
Calcium |
WHO ATC |
|
0-L |
A12AA01 |
calcium phosphate |
WHO ATC |
|
0-L |
A12AA02 |
calcium glubionate |
WHO ATC |
|
0-L |
A12AA03 |
calcium gluconate |
WHO ATC |
|
0-L |
A12AA04 |
calcium carbonate |
WHO ATC |
|
0-L |
A12AA05 |
calcium lactate |
WHO ATC |
|
0-L |
A12AA06 |
calcium lactate gluconate |
WHO ATC |
|
0-L |
A12AA07 |
calcium chloride |
WHO ATC |
|
0-L |
A12AA08 |
calcium glycerylphosphate |
WHO ATC |
|
0-L |
A12AA09 |
calcium citrate lysine complex |
WHO ATC |
|
0-L |
A12AA10 |
calcium glucoheptonate |
WHO ATC |
|
0-L |
A12AA11 |
calcium pangamate |
WHO ATC |
|
0-L |
A12AA12 |
calcium acetate anhydrous |
WHO ATC |
|
0-L |
A12AA20 |
calcium (different salts in combination) |
WHO ATC |
|
0-L |
A12AA30 |
calcium laevulate |
WHO ATC |
|
0-L |
A12AX |
Calcium, combinations with other drugs |
WHO ATC |
|
0-L |
A12B |
POTASSIUM |
WHO ATC |
|
0-L |
A12BA |
Potassium |
WHO ATC |
|
0-L |
A12BA01 |
potassium chloride |
WHO ATC |
|
0-L |
A12BA02 |
potassium citrate |
WHO ATC |
|
0-L |
A12BA03 |
potassium hydrogentartrate |
WHO ATC |
|
0-L |
A12BA04 |
potassium hydrogencarbonate |
WHO ATC |
|
0-L |
A12BA05 |
potassium gluconate |
WHO ATC |
|
0-L |
A12BA30 |
combinations |
WHO ATC |
|
0-L |
A12BA51 |
potassium chloride, combinations |
WHO ATC |
|
0-L |
A12C |
OTHER MINERAL SUPPLEMENTS |
WHO ATC |
|
0-L |
A12CA |
Sodium |
WHO ATC |
|
0-L |
A12CA01 |
sodium chloride |
WHO ATC |
|
0-L |
A12CA02 |
sodium sulfate |
WHO ATC |
|
0-L |
A12CB |
Zinc |
WHO ATC |
|
0-L |
A12CB01 |
zinc sulfate |
WHO ATC |
|
0-L |
A12CB02 |
zinc gluconate |
WHO ATC |
|
0-L |
A12CB03 |
zinc protein complex |
WHO ATC |
|
0-L |
A12CC |
Magnesium |
WHO ATC |
|
0-L |
A12CC01 |
magnesium chloride |
WHO ATC |
|
0-L |
A12CC02 |
magnesium sulfate |
WHO ATC |
|
0-L |
A12CC03 |
magnesium gluconate |
WHO ATC |
|
0-L |
A12CC04 |
magnesium citrate |
WHO ATC |
|
0-L |
A12CC05 |
magnesium aspartate |
WHO ATC |
|
0-L |
A12CC06 |
magnesium lactate |
WHO ATC |
|
0-L |
A12CC07 |
magnesium levulinate |
WHO ATC |
|
0-L |
A12CC08 |
magnesium pidolate |
WHO ATC |
|
0-L |
A12CC09 |
magnesium orotate |
WHO ATC |
|
0-L |
A12CC10 |
magnesium oxide |
WHO ATC |
|
0-L |
A12CC30 |
magnesium (different salts in combination) |
WHO ATC |
|
0-L |
A12CD |
Fluoride |
WHO ATC |
|
0-L |
A12CD01 |
sodium fluoride |
WHO ATC |
|
0-L |
A12CD02 |
sodium monofluorophosphate |
WHO ATC |
|
0-L |
A12CD51 |
fluoride, combinations |
WHO ATC |
|
0-L |
A12CE |
Selenium |
WHO ATC |
|
0-L |
A12CE01 |
sodium selenate |
WHO ATC |
|
0-L |
A12CE02 |
sodium selenite |
WHO ATC |
|
0-L |
A12CX |
Other mineral products |
WHO ATC |
|
0-L |
A13 |
TONICS |
WHO ATC |
|
0-L |
A13A |
TONICS |
WHO ATC |
|
0-L |
A14 |
ANABOLIC AGENTS FOR SYSTEMIC USE |
WHO ATC |
|
0-L |
A14A |
ANABOLIC STEROIDS |
WHO ATC |
|
0-L |
A14AA |
Androstan derivatives |
WHO ATC |
|
0-L |
A14AA01 |
androstanolone |
WHO ATC |
|
0-L |
A14AA02 |
stanozolol |
WHO ATC |
|
0-L |
A14AA03 |
metandienone |
WHO ATC |
|
0-L |
A14AA04 |
metenolone |
WHO ATC |
|
0-L |
A14AA05 |
oxymetholone |
WHO ATC |
|
0-L |
A14AA06 |
quinbolone |
WHO ATC |
|
0-L |
A14AA07 |
prasterone |
WHO ATC |
|
0-L |
A14AA08 |
oxandrolone |
WHO ATC |
|
0-L |
A14AA09 |
norethandrolone |
WHO ATC |
|
0-L |
A14AB |
Estren derivatives |
WHO ATC |
|
0-L |
A14AB01 |
nandrolone |
WHO ATC |
|
0-L |
A14AB02 |
ethylestrenol |
WHO ATC |
|
0-L |
A14AB03 |
oxabolone cipionate |
WHO ATC |
|
0-L |
A14B |
OTHER ANABOLIC AGENTS |
WHO ATC |
|
0-L |
A15 |
APPETITE STIMULANTS |
WHO ATC |
|
0-L |
A16 |
OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS |
WHO ATC |
|
0-L |
A16A |
OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS |
WHO ATC |
|
0-L |
A16AA |
Amino acids and derivatives |
WHO ATC |
|
0-L |
A16AA01 |
levocarnitine |
WHO ATC |
|
0-L |
A16AA02 |
ademetionine |
WHO ATC |
|
0-L |
A16AA03 |
glutamine |
WHO ATC |
|
0-L |
A16AA04 |
mercaptamine |
WHO ATC |
|
0-L |
A16AA05 |
carglumic acid |
WHO ATC |
|
0-L |
A16AA06 |
betaine |
WHO ATC |
|
0-L |
A16AB |
Enzymes |
WHO ATC |
|
0-L |
A16AB01 |
alglucerase |
WHO ATC |
|
0-L |
A16AB02 |
imiglucerase |
WHO ATC |
|
0-L |
A16AB03 |
agalsidase alfa |
WHO ATC |
|
0-L |
A16AB04 |
agalsidase beta |
WHO ATC |
|
0-L |
A16AB05 |
laronidase |
WHO ATC |
|
0-L |
A16AB06 |
sacrosidase |
WHO ATC |
|
0-L |
A16AB07 |
alglucosidase alfa |
WHO ATC |
|
0-L |
A16AB08 |
galsulfase |
WHO ATC |
|
0-L |
A16AB09 |
idursulfase |
WHO ATC |
|
0-L |
A16AX |
Various alimentary tract and metabolism products |
WHO ATC |
|
0-L |
A16AX01 |
tioctic acid |
WHO ATC |
|
0-L |
A16AX02 |
anethole trithione |
WHO ATC |
|
0-L |
A16AX03 |
sodium phenylbutyrate |
WHO ATC |
|
0-L |
A16AX04 |
nitisinone |
WHO ATC |
|
0-L |
A16AX05 |
zinc acetate |
WHO ATC |
|
0-L |
A16AX06 |
miglustat |
WHO ATC |
|
0-L |
A16AX07 |
sapropterin |
WHO ATC |
|
0-L |
B |
BLOOD AND BLOOD FORMING ORGANS |
WHO ATC |
|
0-L |
B01 |
ANTITHROMBOTIC AGENTS |
WHO ATC |
|
0-L |
B01A |
ANTITHROMBOTIC AGENTS |
WHO ATC |
|
0-L |
B01AA |
Vitamin K antagonists |
WHO ATC |
|
0-L |
B01AA01 |
dicoumarol |
WHO ATC |
|
0-L |
B01AA02 |
phenindione |
WHO ATC |
|
0-L |
B01AA03 |
warfarin |
WHO ATC |
|
0-L |
B01AA04 |
phenprocoumon |
WHO ATC |
|
0-L |
B01AA07 |
acenocoumarol |
WHO ATC |
|
0-L |
B01AA08 |
ethyl biscoumacetate |
WHO ATC |
|
0-L |
B01AA09 |
clorindione |
WHO ATC |
|
0-L |
B01AA10 |
diphenadione |
WHO ATC |
|
0-L |
B01AA11 |
tioclomarol |
WHO ATC |
|
0-L |
B01AB |
Heparin group |
WHO ATC |
|
0-L |
B01AB01 |
heparin |
WHO ATC |
|
0-L |
B01AB02 |
antithrombin III |
WHO ATC |
|
0-L |
B01AB04 |
dalteparin |
WHO ATC |
|
0-L |
B01AB05 |
enoxaparin |
WHO ATC |
|
0-L |
B01AB06 |
nadroparin |
WHO ATC |
|
0-L |
B01AB07 |
parnaparin |
WHO ATC |
|
0-L |
B01AB08 |
reviparin |
WHO ATC |
|
0-L |
B01AB09 |
danaparoid |
WHO ATC |
|
0-L |
B01AB10 |
tinzaparin |
WHO ATC |
|
0-L |
B01AB11 |
sulodexide |
WHO ATC |
|
0-L |
B01AB12 |
bemiparin |
WHO ATC |
|
0-L |
B01AB51 |
heparin, combinations |
WHO ATC |
|
0-L |
B01AC |
Platelet aggregation inhibitors excl. heparin |
WHO ATC |
|
0-L |
B01AC01 |
ditazole |
WHO ATC |
|
0-L |
B01AC02 |
cloricromen |
WHO ATC |
|
0-L |
B01AC03 |
picotamide |
WHO ATC |
|
0-L |
B01AC04 |
clopidogrel |
WHO ATC |
|
0-L |
B01AC05 |
ticlopidine |
WHO ATC |
|
0-L |
B01AC06 |
acetylsalicylic acid |
WHO ATC |
|
0-L |
B01AC07 |
dipyridamole |
WHO ATC |
|
0-L |
B01AC08 |
carbasalate calcium |
WHO ATC |
|
0-L |
B01AC09 |
epoprostenol |
WHO ATC |
|
0-L |
B01AC10 |
indobufen |
WHO ATC |
|
0-L |
B01AC11 |
iloprost |
WHO ATC |
|
0-L |
B01AC13 |
abciximab |
WHO ATC |
|
0-L |
B01AC15 |
aloxiprin |
WHO ATC |
|
0-L |
B01AC16 |
eptifibatide |
WHO ATC |
|
0-L |
B01AC17 |
tirofiban |
WHO ATC |
|
0-L |
B01AC18 |
triflusal |
WHO ATC |
|
0-L |
B01AC19 |
beraprost |
WHO ATC |
|
0-L |
B01AC21 |
treprostinil |
WHO ATC |
|
0-L |
B01AC22 |
prasugrel |
WHO ATC |
|
0-L |
B01AC30 |
combinations |
WHO ATC |
|
0-L |
B01AD |
Enzymes |
WHO ATC |
|
0-L |
B01AD01 |
streptokinase |
WHO ATC |
|
0-L |
B01AD02 |
alteplase |
WHO ATC |
|
0-L |
B01AD03 |
anistreplase |
WHO ATC |
|
0-L |
B01AD04 |
urokinase |
WHO ATC |
|
0-L |
B01AD05 |
fibrinolysin |
WHO ATC |
|
0-L |
B01AD06 |
brinase |
WHO ATC |
|
0-L |
B01AD07 |
reteplase |
WHO ATC |
|
0-L |
B01AD08 |
saruplase |
WHO ATC |
|
0-L |
B01AD09 |
ancrod |
WHO ATC |
|
0-L |
B01AD10 |
drotrecogin alfa (activated) |
WHO ATC |
|
0-L |
B01AD11 |
tenecteplase |
WHO ATC |
|
0-L |
B01AD12 |
protein C |
WHO ATC |
|
0-L |
B01AE |
Direct thrombin inhibitors |
WHO ATC |
|
0-L |
B01AE01 |
desirudin |
WHO ATC |
|
0-L |
B01AE02 |
lepirudin |
WHO ATC |
|
0-L |
B01AE03 |
argatroban |
WHO ATC |
|
0-L |
B01AE04 |
melagatran |
WHO ATC |
|
0-L |
B01AE05 |
ximelagatran |
WHO ATC |
|
0-L |
B01AE06 |
bivalirudin |
WHO ATC |
|
0-L |
B01AE07 |
dabigatran etexilate |
WHO ATC |
|
0-L |
B01AX |
Other antithrombotic agents |
WHO ATC |
|
0-L |
B01AX01 |
defibrotide |
WHO ATC |
|
0-L |
B01AX04 |
dermatan sulfate |
WHO ATC |
|
0-L |
B01AX05 |
fondaparinux |
WHO ATC |
|
0-L |
B01AX06 |
rivaroxaban |
WHO ATC |
|
0-L |
B02 |
ANTIHEMORRHAGICS |
WHO ATC |
|
0-L |
B02A |
ANTIFIBRINOLYTICS |
WHO ATC |
|
0-L |
B02AA |
Amino acids |
WHO ATC |
|
0-L |
B02AA01 |
aminocaproic acid |
WHO ATC |
|
0-L |
B02AA02 |
tranexamic acid |
WHO ATC |
|
0-L |
B02AA03 |
aminomethylbenzoic acid |
WHO ATC |
|
0-L |
B02AB |
Proteinase inhibitors |
WHO ATC |
|
0-L |
B02AB01 |
aprotinin |
WHO ATC |
|
0-L |
B02AB02 |
alfa1 antitrypsin |
WHO ATC |
|
0-L |
B02AB03 |
c1-inhibitor |
WHO ATC |
|
0-L |
B02AB04 |
camostat |
WHO ATC |
|
0-L |
B02B |
VITAMIN K AND OTHER HEMOSTATICS |
WHO ATC |
|
0-L |
B02BA |
Vitamin K |
WHO ATC |
|
0-L |
B02BA01 |
phytomenadione |
WHO ATC |
|
0-L |
B02BA02 |
menadione |
WHO ATC |
|
0-L |
B02BB |
Fibrinogen |
WHO ATC |
|
0-L |
B02BB01 |
human fibrinogen |
WHO ATC |
|
0-L |
B02BC |
Local hemostatics |
WHO ATC |
|
0-L |
B02BC01 |
absorbable gelatin sponge |
WHO ATC |
|
0-L |
B02BC02 |
oxidized cellulose |
WHO ATC |
|
0-L |
B02BC03 |
tetragalacturonic acid hydroxymethylester |
WHO ATC |
|
0-L |
B02BC05 |
adrenalone |
WHO ATC |
|
0-L |
B02BC06 |
thrombin |
WHO ATC |
|
0-L |
B02BC07 |
collagen |
WHO ATC |
|
0-L |
B02BC08 |
calcium alginate |
WHO ATC |
|
0-L |
B02BC09 |
epinephrine |
WHO ATC |
|
0-L |
B02BC10 |
fibrinogen, human |
WHO ATC |
|
0-L |
B02BC30 |
combinations |
WHO ATC |
|
0-L |
B02BD |
Blood coagulation factors |
WHO ATC |
|
0-L |
B02BD01 |
coagulation factor IX, II, VII and X in combination |
WHO ATC |
|
0-L |
B02BD02 |
coagulation factor VIII |
WHO ATC |
|
0-L |
B02BD03 |
factor VIII inhibitor bypassing activity |
WHO ATC |
|
0-L |
B02BD04 |
coagulation factor IX |
WHO ATC |
|
0-L |
B02BD05 |
coagulation factor VII |
WHO ATC |
|
0-L |
B02BD06 |
von Willebrand factor and coagulation factor VIII in combination |
WHO ATC |
|
0-L |
B02BD07 |
coagulation factor XIII |
WHO ATC |
|
0-L |
B02BD08 |
eptacog alfa (activated) |
WHO ATC |
|
0-L |
B02BD09 |
nonacog alfa |
WHO ATC |
|
0-L |
B02BD30 |
thrombin |
WHO ATC |
|
0-L |
B02BX |
Other systemic hemostatics |
WHO ATC |
|
0-L |
B02BX01 |
etamsylate |
WHO ATC |
|
0-L |
B02BX02 |
carbazochrome |
WHO ATC |
|
0-L |
B02BX03 |
batroxobin |
WHO ATC |
|
0-L |
B02BX04 |
romiplostim |
WHO ATC |
|
0-L |
B02BX05 |
eltrombopag |
WHO ATC |
|
0-L |
B03 |
ANTIANEMIC PREPARATIONS |
WHO ATC |
|
0-L |
B03A |
IRON PREPARATIONS |
WHO ATC |
|
0-L |
B03AA |
Iron bivalent, oral preparations |
WHO ATC |
|
0-L |
B03AA01 |
ferrous glycine sulfate |
WHO ATC |
|
0-L |
B03AA02 |
ferrous fumarate |
WHO ATC |
|
0-L |
B03AA03 |
ferrous gluconate |
WHO ATC |
|
0-L |
B03AA04 |
ferrous carbonate |
WHO ATC |
|
0-L |
B03AA05 |
ferrous chloride |
WHO ATC |
|
0-L |
B03AA06 |
ferrous succinate |
WHO ATC |
|
0-L |
B03AA07 |
ferrous sulfate |
WHO ATC |
|
0-L |
B03AA08 |
ferrous tartrate |
WHO ATC |
|
0-L |
B03AA09 |
ferrous aspartate |
WHO ATC |
|
0-L |
B03AA10 |
ferrous ascorbate |
WHO ATC |
|
0-L |
B03AA11 |
ferrous iodine |
WHO ATC |
|
0-L |
B03AB |
Iron trivalent, oral preparations |
WHO ATC |
|
0-L |
B03AB01 |
ferric sodium citrate |
WHO ATC |
|
0-L |
B03AB02 |
saccharated iron oxide |
WHO ATC |
|
0-L |
B03AB03 |
sodium feredetate |
WHO ATC |
|
0-L |
B03AB04 |
ferric hydroxide |
WHO ATC |
|
0-L |
B03AB05 |
dextriferron |
WHO ATC |
|
0-L |
B03AB06 |
ferric citrate |
WHO ATC |
|
0-L |
B03AB07 |
chondroitin sulfate-iron complex |
WHO ATC |
|
0-L |
B03AB08 |
ferric acetyl transferrin |
WHO ATC |
|
0-L |
B03AB09 |
ferric proteinsuccinylate |
WHO ATC |
|
0-L |
B03AC |
Iron trivalent, parenteral preparations |
WHO ATC |
|
0-L |
B03AC01 |
dextriferron |
WHO ATC |
|
0-L |
B03AC02 |
saccharated iron oxide |
WHO ATC |
|
0-L |
B03AC03 |
iron-sorbitol-citric acid complex |
WHO ATC |
|
0-L |
B03AC05 |
ferric sorbitol gluconic acid complex |
WHO ATC |
|
0-L |
B03AC06 |
ferric oxide dextran complex |
WHO ATC |
|
0-L |
B03AC07 |
ferric sodium gluconate complex |
WHO ATC |
|
0-L |
B03AD |
Iron in combination with folic acid |
WHO ATC |
|
0-L |
B03AD01 |
ferrous amino acid complex |
WHO ATC |
|
0-L |
B03AD02 |
ferrous fumarate |
WHO ATC |
|
0-L |
B03AD03 |
ferrous sulfate |
WHO ATC |
|
0-L |
B03AD04 |
dextriferron |
WHO ATC |
|
0-L |
B03AE |
Iron in other combinations |
WHO ATC |
|
0-L |
B03AE01 |
iron, vitamin B12 and folic acid |
WHO ATC |
|
0-L |
B03AE02 |
iron, multivitamins and folic acid |
WHO ATC |
|
0-L |
B03AE03 |
iron and multivitamins |
WHO ATC |
|
0-L |
B03AE04 |
iron, multivitamins and minerals |
WHO ATC |
|
0-L |
B03AE10 |
various combinations |
WHO ATC |
|
0-L |
B03B |
VITAMIN B12 AND FOLIC ACID |
WHO ATC |
|
0-L |
B03BA |
Vitamin B12 (cyanocobalamin and analogues) |
WHO ATC |
|
0-L |
B03BA01 |
cyanocobalamin |
WHO ATC |
|
0-L |
B03BA02 |
cyanocobalamin tannin complex |
WHO ATC |
|
0-L |
B03BA03 |
hydroxocobalamin |
WHO ATC |
|
0-L |
B03BA04 |
cobamamide |
WHO ATC |
|
0-L |
B03BA05 |
mecobalamin |
WHO ATC |
|
0-L |
B03BA51 |
cyanocobalamin, combinations |
WHO ATC |
|
0-L |
B03BA53 |
hydroxocobalamin, combinations |
WHO ATC |
|
0-L |
B03BB |
Folic acid and derivatives |
WHO ATC |
|
0-L |
B03BB01 |
folic acid |
WHO ATC |
|
0-L |
B03BB51 |
folic acid, combinations |
WHO ATC |
|
0-L |
B03X |
OTHER ANTIANEMIC PREPARATIONS |
WHO ATC |
|
0-L |
B03XA |
Other antianemic preparations |
WHO ATC |
|
0-L |
B03XA01 |
erythropoietin |
WHO ATC |
|
0-L |
B03XA02 |
darbepoetin alfa |
WHO ATC |
|
0-L |
B03XA03 |
methoxy polyethylene glycol-epoetin beta |
WHO ATC |
|
0-L |
B05 |
BLOOD SUBSTITUTES AND PERFUSION SOLUTIONS |
WHO ATC |
|
0-L |
B05A |
BLOOD AND RELATED PRODUCTS |
WHO ATC |
|
0-L |
B05AA |
Blood substitutes and plasma protein fractions |
WHO ATC |
|
0-L |
B05AA01 |
albumin |
WHO ATC |
|
0-L |
B05AA02 |
other plasma protein fractions |
WHO ATC |
|
0-L |
B05AA03 |
fluorocarbon blood substitutes |
WHO ATC |
|
0-L |
B05AA05 |
dextran |
WHO ATC |
|
0-L |
B05AA06 |
gelatin agents |
WHO ATC |
|
0-L |
B05AA07 |
hydroxyethylstarch |
WHO ATC |
|
0-L |
B05AA08 |
hemoglobin crosfumaril |
WHO ATC |
|
0-L |
B05AA09 |
hemoglobin raffimer |
WHO ATC |
|
0-L |
B05AA10 |
hemoglobin glutamer (bovine) |
WHO ATC |
|
0-L |
B05AX |
Other blood products |
WHO ATC |
|
0-L |
B05AX01 |
erythrocytes |
WHO ATC |
|
0-L |
B05AX02 |
thrombocytes |
WHO ATC |
|
0-L |
B05AX03 |
blood plasma |
WHO ATC |
|
0-L |
B05AX04 |
stem cells from umbilical cord blood |
WHO ATC |
|
0-L |
B05B |
I.V. SOLUTIONS |
WHO ATC |
|
0-L |
B05BA |
Solutions for parenteral nutrition |
WHO ATC |
|
0-L |
B05BA01 |
amino acids |
WHO ATC |
|
0-L |
B05BA02 |
fat emulsions |
WHO ATC |
|
0-L |
B05BA03 |
carbohydrates |
WHO ATC |
|
0-L |
B05BA04 |
protein hydrolysates |
WHO ATC |
|
0-L |
B05BA10 |
combinations |
WHO ATC |
|
0-L |
B05BB |
Solutions affecting the electrolyte balance |
WHO ATC |
|
0-L |
B05BB01 |
electrolytes |
WHO ATC |
|
0-L |
B05BB02 |
electrolytes with carbohydrates |
WHO ATC |
|
0-L |
B05BB03 |
trometamol |
WHO ATC |
|
0-L |
B05BC |
Solutions producing osmotic diuresis |
WHO ATC |
|
0-L |
B05BC01 |
mannitol |
WHO ATC |
|
0-L |
B05BC02 |
carbamide |
WHO ATC |
|
0-L |
B05C |
IRRIGATING SOLUTIONS |
WHO ATC |
|
0-L |
B05CA |
Antiinfectives |
WHO ATC |
|
0-L |
B05CA01 |
cetylpyridinium |
WHO ATC |
|
0-L |
B05CA02 |
chlorhexidine |
WHO ATC |
|
0-L |
B05CA03 |
nitrofural |
WHO ATC |
|
0-L |
B05CA04 |
sulfamethizole |
WHO ATC |
|
0-L |
B05CA05 |
taurolidine |
WHO ATC |
|
0-L |
B05CA06 |
mandelic acid |
WHO ATC |
|
0-L |
B05CA07 |
noxytiolin |
WHO ATC |
|
0-L |
B05CA08 |
ethacridine lactate |
WHO ATC |
|
0-L |
B05CA09 |
neomycin |
WHO ATC |
|
0-L |
B05CA10 |
combinations |
WHO ATC |
|
0-L |
B05CB |
Salt solutions |
WHO ATC |
|
0-L |
B05CB01 |
sodium chloride |
WHO ATC |
|
0-L |
B05CB02 |
sodium citrate |
WHO ATC |
|
0-L |
B05CB03 |
magnesium citrate |
WHO ATC |
|
0-L |
B05CB04 |
sodium bicarbonate |
WHO ATC |
|
0-L |
B05CB10 |
combinations |
WHO ATC |
|
0-L |
B05CX |
Other irrigating solutions |
WHO ATC |
|
0-L |
B05CX01 |
glucose |
WHO ATC |
|
0-L |
B05CX02 |
sorbitol |
WHO ATC |
|
0-L |
B05CX03 |
glycine |
WHO ATC |
|
0-L |
B05CX04 |
mannitol |
WHO ATC |
|
0-L |
B05CX10 |
combinations |
WHO ATC |
|
0-L |
B05D |
PERITONEAL DIALYTICS |
WHO ATC |
|
0-L |
B05DA |
Isotonic solutions |
WHO ATC |
|
0-L |
B05DB |
Hypertonic solutions |
WHO ATC |
|
0-L |
B05X |
I.V. SOLUTION ADDITIVES |
WHO ATC |
|
0-L |
B05XA |
Electrolyte solutions |
WHO ATC |
|
0-L |
B05XA01 |
potassium chloride |
WHO ATC |
|
0-L |
B05XA02 |
sodium bicarbonate |
WHO ATC |
|
0-L |
B05XA03 |
sodium chloride |
WHO ATC |
|
0-L |
B05XA04 |
ammonium chloride |
WHO ATC |
|
0-L |
B05XA05 |
magnesium sulfate |
WHO ATC |
|
0-L |
B05XA06 |
potassium phosphate, incl. comb. with other potassium salts |
WHO ATC |
|
0-L |
B05XA07 |
calcium chloride |
WHO ATC |
|
0-L |
B05XA08 |
sodium acetate |
WHO ATC |
|
0-L |
B05XA09 |
sodium phosphate |
WHO ATC |
|
0-L |
B05XA10 |
magnesium phosphate |
WHO ATC |
|
0-L |
B05XA11 |
magnesium chloride |
WHO ATC |
|
0-L |
B05XA12 |
zinc chloride |
WHO ATC |
|
0-L |
B05XA13 |
hydrochloric acid |
WHO ATC |
|
0-L |
B05XA14 |
sodium glycerophosphate |
WHO ATC |
|
0-L |
B05XA15 |
potassium lactate |
WHO ATC |
|
0-L |
B05XA16 |
cardioplegia solutions |
WHO ATC |
|
0-L |
B05XA17 |
potassium acetate |
WHO ATC |
|
0-L |
B05XA30 |
combinations of electrolytes |
WHO ATC |
|
0-L |
B05XA31 |
electrolytes in combination with other drugs |
WHO ATC |
|
0-L |
B05XB |
Amino acids |
WHO ATC |
|
0-L |
B05XB01 |
arginine hydrochloride |
WHO ATC |
|
0-L |
B05XB02 |
alanyl glutamine |
WHO ATC |
|
0-L |
B05XB03 |
lysine |
WHO ATC |
|
0-L |
B05XC |
Vitamins |
WHO ATC |
|
0-L |
B05XX |
Other i.v. solution additives |
WHO ATC |
|
0-L |
B05XX02 |
trometamol |
WHO ATC |
|
0-L |
B05Z |
HEMODIALYTICS AND HEMOFILTRATES |
WHO ATC |
|
0-L |
B05ZA |
Hemodialytics, concentrates |
WHO ATC |
|
0-L |
B05ZB |
Hemofiltrates |
WHO ATC |
|
0-L |
B06 |
OTHER HEMATOLOGICAL AGENTS |
WHO ATC |
|
0-L |
B06A |
OTHER HEMATOLOGICAL AGENTS |
WHO ATC |
|
0-L |
B06AA |
Enzymes |
WHO ATC |
|
0-L |
B06AA02 |
fibrinolysin and desoxyribonuclease |
WHO ATC |
|
0-L |
B06AA03 |
hyaluronidase |
WHO ATC |
|
0-L |
B06AA04 |
chymotrypsin |
WHO ATC |
|
0-L |
B06AA07 |
trypsin |
WHO ATC |
|
0-L |
B06AA10 |
desoxyribonuclease |
WHO ATC |
|
0-L |
B06AA11 |
bromelains |
WHO ATC |
|
0-L |
B06AA55 |
streptokinase, combinations |
WHO ATC |
|
0-L |
B06AB |
Other hem products |
WHO ATC |
|
0-L |
B06AB01 |
hematin |
WHO ATC |
|
0-L |
C |
CARDIOVASCULAR SYSTEM |
WHO ATC |
|
0-L |
C01 |
CARDIAC THERAPY |
WHO ATC |
|
0-L |
C01A |
CARDIAC GLYCOSIDES |
WHO ATC |
|
0-L |
C01AA |
Digitalis glycosides |
WHO ATC |
|
0-L |
C01AA01 |
acetyldigitoxin |
WHO ATC |
|
0-L |
C01AA02 |
acetyldigoxin |
WHO ATC |
|
0-L |
C01AA03 |
digitalis leaves |
WHO ATC |
|
0-L |
C01AA04 |
digitoxin |
WHO ATC |
|
0-L |
C01AA05 |
digoxin |
WHO ATC |
|
0-L |
C01AA06 |
lanatoside C |
WHO ATC |
|
0-L |
C01AA07 |
deslanoside |
WHO ATC |
|
0-L |
C01AA08 |
metildigoxin |
WHO ATC |
|
0-L |
C01AA09 |
gitoformate |
WHO ATC |
|
0-L |
C01AA52 |
acetyldigoxin, combinations |
WHO ATC |
|
0-L |
C01AB |
Scilla glycosides |
WHO ATC |
|
0-L |
C01AB01 |
proscillaridin |
WHO ATC |
|
0-L |
C01AB51 |
proscillaridin, combinations |
WHO ATC |
|
0-L |
C01AC |
Strophantus glycosides |
WHO ATC |
|
0-L |
C01AC01 |
g-strophanthin |
WHO ATC |
|
0-L |
C01AC03 |
cymarin |
WHO ATC |
|
0-L |
C01AX |
Other cardiac glycosides |
WHO ATC |
|
0-L |
C01AX02 |
peruvoside |
WHO ATC |
|
0-L |
C01B |
ANTIARRHYTHMICS, CLASS I AND III |
WHO ATC |
|
0-L |
C01BA |
Antiarrhythmics, class Ia |
WHO ATC |
|
0-L |
C01BA01 |
quinidine |
WHO ATC |
|
0-L |
C01BA02 |
procainamide |
WHO ATC |
|
0-L |
C01BA03 |
disopyramide |
WHO ATC |
|
0-L |
C01BA04 |
sparteine |
WHO ATC |
|
0-L |
C01BA05 |
ajmaline |
WHO ATC |
|
0-L |
C01BA08 |
prajmaline |
WHO ATC |
|
0-L |
C01BA12 |
lorajmine |
WHO ATC |
|
0-L |
C01BA51 |
quinidine, combinations excl. psycholeptics |
WHO ATC |
|
0-L |
C01BA71 |
quinidine, combinations with psycholeptics |
WHO ATC |
|
0-L |
C01BB |
Antiarrhythmics, class Ib |
WHO ATC |
|
0-L |
C01BB01 |
lidocaine |
WHO ATC |
|
0-L |
C01BB02 |
mexiletine |
WHO ATC |
|
0-L |
C01BB03 |
tocainide |
WHO ATC |
|
0-L |
C01BB04 |
aprindine |
WHO ATC |
|
0-L |
C01BC |
Antiarrhythmics, class Ic |
WHO ATC |
|
0-L |
C01BC03 |
propafenone |
WHO ATC |
|
0-L |
C01BC04 |
flecainide |
WHO ATC |
|
0-L |
C01BC07 |
lorcainide |
WHO ATC |
|
0-L |
C01BC08 |
encainide |
WHO ATC |
|
0-L |
C01BD |
Antiarrhythmics, class III |
WHO ATC |
|
0-L |
C01BD01 |
amiodarone |
WHO ATC |
|
0-L |
C01BD02 |
bretylium tosilate |
WHO ATC |
|
0-L |
C01BD03 |
bunaftine |
WHO ATC |
|
0-L |
C01BD04 |
dofetilide |
WHO ATC |
|
0-L |
C01BD05 |
ibutilide |
WHO ATC |
|
0-L |
C01BD06 |
tedisamil |
WHO ATC |
|
0-L |
C01BG |
Other class I antiarrhythmics |
WHO ATC |
|
0-L |
C01BG01 |
moracizine |
WHO ATC |
|
0-L |
C01BG07 |
cibenzoline |
WHO ATC |
|
0-L |
C01C |
CARDIAC STIMULANTS EXCL. CARDIAC GLYCOSIDES |
WHO ATC |
|
0-L |
C01CA |
Adrenergic and dopaminergic agents |
WHO ATC |
|
0-L |
C01CA01 |
etilefrine |
WHO ATC |
|
0-L |
C01CA02 |
isoprenaline |
WHO ATC |
|
0-L |
C01CA03 |
norepinephrine |
WHO ATC |
|
0-L |
C01CA04 |
dopamine |
WHO ATC |
|
0-L |
C01CA05 |
norfenefrine |
WHO ATC |
|
0-L |
C01CA06 |
phenylephrine |
WHO ATC |
|
0-L |
C01CA07 |
dobutamine |
WHO ATC |
|
0-L |
C01CA08 |
oxedrine |
WHO ATC |
|
0-L |
C01CA09 |
metaraminol |
WHO ATC |
|
0-L |
C01CA10 |
methoxamine |
WHO ATC |
|
0-L |
C01CA11 |
mephentermine |
WHO ATC |
|
0-L |
C01CA12 |
dimetofrine |
WHO ATC |
|
0-L |
C01CA13 |
prenalterol |
WHO ATC |
|
0-L |
C01CA14 |
dopexamine |
WHO ATC |
|
0-L |
C01CA15 |
gepefrine |
WHO ATC |
|
0-L |
C01CA16 |
ibopamine |
WHO ATC |
|
0-L |
C01CA17 |
midodrine |
WHO ATC |
|
0-L |
C01CA18 |
octopamine |
WHO ATC |
|
0-L |
C01CA19 |
fenoldopam |
WHO ATC |
|
0-L |
C01CA21 |
cafedrine |
WHO ATC |
|
0-L |
C01CA22 |
arbutamine |
WHO ATC |
|
0-L |
C01CA23 |
theodrenaline |
WHO ATC |
|
0-L |
C01CA24 |
epinephrine |
WHO ATC |
|
0-L |
C01CA30 |
combinations |
WHO ATC |
|
0-L |
C01CA51 |
etilefrine, combinations |
WHO ATC |
|
0-L |
C01CE |
Phosphodiesterase inhibitors |
WHO ATC |
|
0-L |
C01CE01 |
amrinone |
WHO ATC |
|
0-L |
C01CE02 |
milrinone |
WHO ATC |
|
0-L |
C01CE03 |
enoximone |
WHO ATC |
|
0-L |
C01CE04 |
bucladesine |
WHO ATC |
|
0-L |
C01CX |
Other cardiac stimulants |
WHO ATC |
|
0-L |
C01CX06 |
angiotensinamide |
WHO ATC |
|
0-L |
C01CX07 |
xamoterol |
WHO ATC |
|
0-L |
C01CX08 |
levosimendan |
WHO ATC |
|
0-L |
C01D |
VASODILATORS USED IN CARDIAC DISEASES |
WHO ATC |
|
0-L |
C01DA |
Organic nitrates |
WHO ATC |
|
0-L |
C01DA02 |
glyceryl trinitrate |
WHO ATC |
|
0-L |
C01DA04 |
methylpropylpropanediol dinitrate |
WHO ATC |
|
0-L |
C01DA05 |
pentaerithrityl tetranitrate |
WHO ATC |
|
0-L |
C01DA07 |
propatylnitrate |
WHO ATC |
|
0-L |
C01DA08 |
isosorbide dinitrate |
WHO ATC |
|
0-L |
C01DA09 |
trolnitrate |
WHO ATC |
|
0-L |
C01DA13 |
eritrityl tetranitrate |
WHO ATC |
|
0-L |
C01DA14 |
isosorbide mononitrate |
WHO ATC |
|
0-L |
C01DA20 |
organic nitrates in combination |
WHO ATC |
|
0-L |
C01DA38 |
tenitramine |
WHO ATC |
|
0-L |
C01DA52 |
glyceryl trinitrate, combinations |
WHO ATC |
|
0-L |
C01DA54 |
methylpropylpropanediol dinitrate, combinations |
WHO ATC |
|
0-L |
C01DA55 |
pentaerithrityl tetranitrate, combinations |
WHO ATC |
|
0-L |
C01DA57 |
propatylnitrate, combinations |
WHO ATC |
|
0-L |
C01DA58 |
isosorbide dinitrate, combinations |
WHO ATC |
|
0-L |
C01DA59 |
trolnitrate, combinations |
WHO ATC |
|
0-L |
C01DA63 |
eritrityl tetranitrate, combinations |
WHO ATC |
|
0-L |
C01DA70 |
organic nitrates in combination with psycholeptics |
WHO ATC |
|
0-L |
C01DB |
Quinolone vasodilators |
WHO ATC |
|
0-L |
C01DB01 |
flosequinan |
WHO ATC |
|
0-L |
C01DX |
Other vasodilators used in cardiac diseases |
WHO ATC |
|
0-L |
C01DX01 |
itramin tosilate |
WHO ATC |
|
0-L |
C01DX02 |
prenylamine |
WHO ATC |
|
0-L |
C01DX03 |
oxyfedrine |
WHO ATC |
|
0-L |
C01DX04 |
benziodarone |
WHO ATC |
|
0-L |
C01DX05 |
carbocromen |
WHO ATC |
|
0-L |
C01DX06 |
hexobendine |
WHO ATC |
|
0-L |
C01DX07 |
etafenone |
WHO ATC |
|
0-L |
C01DX08 |
heptaminol |
WHO ATC |
|
0-L |
C01DX09 |
imolamine |
WHO ATC |
|
0-L |
C01DX10 |
dilazep |
WHO ATC |
|
0-L |
C01DX11 |
trapidil |
WHO ATC |
|
0-L |
C01DX12 |
molsidomine |
WHO ATC |
|
0-L |
C01DX13 |
efloxate |
WHO ATC |
|
0-L |
C01DX14 |
cinepazet |
WHO ATC |
|
0-L |
C01DX15 |
cloridarol |
WHO ATC |
|
0-L |
C01DX16 |
nicorandil |
WHO ATC |
|
0-L |
C01DX18 |
linsidomine |
WHO ATC |
|
0-L |
C01DX19 |
nesiritide |
WHO ATC |
|
0-L |
C01DX51 |
itramin tosilate, combinations |
WHO ATC |
|
0-L |
C01DX52 |
prenylamine, combinations |
WHO ATC |
|
0-L |
C01DX53 |
oxyfedrine, combinations |
WHO ATC |
|
0-L |
C01DX54 |
benziodarone, combinations |
WHO ATC |
|
0-L |
C01E |
OTHER CARDIAC PREPARATIONS |
WHO ATC |
|
0-L |
C01EA |
Prostaglandins |
WHO ATC |
|
0-L |
C01EA01 |
alprostadil |
WHO ATC |
|
0-L |
C01EB |
Other cardiac preparations |
WHO ATC |
|
0-L |
C01EB02 |
camphora |
WHO ATC |
|
0-L |
C01EB03 |
indometacin |
WHO ATC |
|
0-L |
C01EB04 |
crataegus glycosides |
WHO ATC |
|
0-L |
C01EB05 |
creatinolfosfate |
WHO ATC |
|
0-L |
C01EB06 |
fosfocreatine |
WHO ATC |
|
0-L |
C01EB07 |
fructose 1,6-diphosphate |
WHO ATC |
|
0-L |
C01EB09 |
ubidecarenone |
WHO ATC |
|
0-L |
C01EB10 |
adenosine |
WHO ATC |
|
0-L |
C01EB11 |
tiracizine |
WHO ATC |
|
0-L |
C01EB13 |
acadesine |
WHO ATC |
|
0-L |
C01EB15 |
trimetazidine |
WHO ATC |
|
0-L |
C01EB16 |
ibuprofen |
WHO ATC |
|
0-L |
C01EB17 |
ivabradine |
WHO ATC |
|
0-L |
C01EB18 |
ranolazine |
WHO ATC |
|
0-L |
C01EB19 |
icatibant |
WHO ATC |
|
0-L |
C01EB21 |
regadenoson |
WHO ATC |
|
0-L |
C01EX |
Other cardiac combination products |
WHO ATC |
|
0-L |
C02 |
ANTIHYPERTENSIVES |
WHO ATC |
|
0-L |
C02A |
ANTIADRENERGIC AGENTS, CENTRALLY ACTING |
WHO ATC |
|
0-L |
C02AA |
Rauwolfia alkaloids |
WHO ATC |
|
0-L |
C02AA01 |
rescinnamine |
WHO ATC |
|
0-L |
C02AA02 |
reserpine |
WHO ATC |
|
0-L |
C02AA03 |
combinations of rauwolfia alkaloids |
WHO ATC |
|
0-L |
C02AA04 |
rauwolfia alkaloids, whole root |
WHO ATC |
|
0-L |
C02AA05 |
deserpidine |
WHO ATC |
|
0-L |
C02AA06 |
methoserpidine |
WHO ATC |
|
0-L |
C02AA07 |
bietaserpine |
WHO ATC |
|
0-L |
C02AA52 |
reserpine, combinations |
WHO ATC |
|
0-L |
C02AA53 |
combinations of rauwolfia alkoloids, combinations |
WHO ATC |
|
0-L |
C02AA57 |
bietaserpine, combinations |
WHO ATC |
|
0-L |
C02AB |
Methyldopa |
WHO ATC |
|
0-L |
C02AB01 |
methyldopa (levorotatory) |
WHO ATC |
|
0-L |
C02AB02 |
methyldopa (racemic) |
WHO ATC |
|
0-L |
C02AC |
Imidazoline receptor agonists |
WHO ATC |
|
0-L |
C02AC01 |
clonidine |
WHO ATC |
|
0-L |
C02AC02 |
guanfacine |
WHO ATC |
|
0-L |
C02AC04 |
tolonidine |
WHO ATC |
|
0-L |
C02AC05 |
moxonidine |
WHO ATC |
|
0-L |
C02AC06 |
rilmenidine |
WHO ATC |
|
0-L |
C02B |
ANTIADRENERGIC AGENTS, GANGLION-BLOCKING |
WHO ATC |
|
0-L |
C02BA |
Sulfonium derivatives |
WHO ATC |
|
0-L |
C02BA01 |
trimetaphan |
WHO ATC |
|
0-L |
C02BB |
Secondary and tertiary amines |
WHO ATC |
|
0-L |
C02BB01 |
mecamylamine |
WHO ATC |
|
0-L |
C02BC |
Bisquaternary ammonium compounds |
WHO ATC |
|
0-L |
C02C |
ANTIADRENERGIC AGENTS, PERIPHERALLY ACTING |
WHO ATC |
|
0-L |
C02CA |
Alpha-adrenoreceptor antagonists |
WHO ATC |
|
0-L |
C02CA01 |
prazosin |
WHO ATC |
|
0-L |
C02CA02 |
indoramin |
WHO ATC |
|
0-L |
C02CA03 |
trimazosin |
WHO ATC |
|
0-L |
C02CA04 |
doxazosin |
WHO ATC |
|
0-L |
C02CA06 |
urapidil |
WHO ATC |
|
0-L |
C02CC |
Guanidine derivatives |
WHO ATC |
|
0-L |
C02CC01 |
betanidine |
WHO ATC |
|
0-L |
C02CC02 |
guanethidine |
WHO ATC |
|
0-L |
C02CC03 |
guanoxan |
WHO ATC |
|
0-L |
C02CC04 |
debrisoquine |
WHO ATC |
|
0-L |
C02CC05 |
guanoclor |
WHO ATC |
|
0-L |
C02CC06 |
guanazodine |
WHO ATC |
|
0-L |
C02CC07 |
guanoxabenz |
WHO ATC |
|
0-L |
C02D |
ARTERIOLAR SMOOTH MUSCLE, AGENTS ACTING ON |
WHO ATC |
|
0-L |
C02DA |
Thiazide derivatives |
WHO ATC |
|
0-L |
C02DA01 |
diazoxide |
WHO ATC |
|
0-L |
C02DB |
Hydrazinophthalazine derivatives |
WHO ATC |
|
0-L |
C02DB01 |
dihydralazine |
WHO ATC |
|
0-L |
C02DB02 |
hydralazine |
WHO ATC |
|
0-L |
C02DB03 |
endralazine |
WHO ATC |
|
0-L |
C02DB04 |
cadralazine |
WHO ATC |
|
0-L |
C02DC |
Pyrimidine derivatives |
WHO ATC |
|
0-L |
C02DC01 |
minoxidil |
WHO ATC |
|
0-L |
C02DD |
Nitroferricyanide derivatives |
WHO ATC |
|
0-L |
C02DD01 |
nitroprusside |
WHO ATC |
|
0-L |
C02DG |
Guanidine derivatives |
WHO ATC |
|
0-L |
C02DG01 |
pinacidil |
WHO ATC |
|
0-L |
C02K |
OTHER ANTIHYPERTENSIVES |
WHO ATC |
|
0-L |
C02KA |
Alkaloids, excl. rauwolfia |
WHO ATC |
|
0-L |
C02KA01 |
veratrum |
WHO ATC |
|
0-L |
C02KB |
Tyrosine hydroxylase inhibitors |
WHO ATC |
|
0-L |
C02KB01 |
metirosine |
WHO ATC |
|
0-L |
C02KC |
MAO inhibitors |
WHO ATC |
|
0-L |
C02KC01 |
pargyline |
WHO ATC |
|
0-L |
C02KD |
Serotonin antagonists |
WHO ATC |
|
0-L |
C02KD01 |
ketanserin |
WHO ATC |
|
0-L |
C02KX |
Other antihypertensives |
WHO ATC |
|
0-L |
C02KX01 |
bosentan |
WHO ATC |
|
0-L |
C02KX02 |
ambrisentan |
WHO ATC |
|
0-L |
C02KX03 |
sitaxentan |
WHO ATC |
|
0-L |
C02L |
ANTIHYPERTENSIVES AND DIURETICS IN COMBINATION |
WHO ATC |
|
0-L |
C02LA |
Rauwolfia alkaloids and diuretics in combination |
WHO ATC |
|
0-L |
C02LA01 |
reserpine and diuretics |
WHO ATC |
|
0-L |
C02LA02 |
rescinnamine and diuretics |
WHO ATC |
|
0-L |
C02LA03 |
deserpidine and diuretics |
WHO ATC |
|
0-L |
C02LA04 |
methoserpidine and diuretics |
WHO ATC |
|
0-L |
C02LA07 |
bietaserpine and diuretics |
WHO ATC |
|
0-L |
C02LA08 |
rauwolfia alkaloids, whole root and diuretics |
WHO ATC |
|
0-L |
C02LA09 |
syrosingopine and diuretics |
WHO ATC |
|
0-L |
C02LA50 |
comb. of rauwolfia alkaloids and diuretics incl. other combinations |
WHO ATC |
|
0-L |
C02LA51 |
reserpine and diuretics, combinations with other drugs |
WHO ATC |
|
0-L |
C02LA52 |
rescinnamine and diuretics, combinations with other drugs |
WHO ATC |
|
0-L |
C02LA71 |
reserpine and diuretics, combinations with psycholeptics |
WHO ATC |
|
0-L |
C02LB |
Methyldopa and diuretics in combination |
WHO ATC |
|
0-L |
C02LB01 |
methyldopa (levorotatory) and diuretics |
WHO ATC |
|
0-L |
C02LC |
Imidazoline receptor agonists in combination with diuretics |
WHO ATC |
|
0-L |
C02LC01 |
clonidine and diuretics |
WHO ATC |
|
0-L |
C02LC05 |
moxonidine and diuretics |
WHO ATC |
|
0-L |
C02LC51 |
clonidine and diuretics, combinations with other drugs |
WHO ATC |
|
0-L |
C02LE |
Alpha-adrenoreceptor antagonists and diuretics |
WHO ATC |
|
0-L |
C02LE01 |
prazosin and diuretics |
WHO ATC |
|
0-L |
C02LF |
Guanidine derivatives and diuretics |
WHO ATC |
|
0-L |
C02LF01 |
guanethidine and diuretics |
WHO ATC |
|
0-L |
C02LG |
Hydrazinophthalazine derivatives and diuretics |
WHO ATC |
|
0-L |
C02LG01 |
dihydralazine and diuretics |
WHO ATC |
|
0-L |
C02LG02 |
hydralazine and diuretics |
WHO ATC |
|
0-L |
C02LG03 |
picodralazine and diuretics |
WHO ATC |
|
0-L |
C02LG51 |
dihydralazine and diuretics, combinations with other drugs |
WHO ATC |
|
0-L |
C02LG73 |
picodralazine and diuretics, combinations with psycholeptics |
WHO ATC |
|
0-L |
C02LK |
Alkaloids, excl. rauwolfia, in combination with diuretics |
WHO ATC |
|
0-L |
C02LK01 |
veratrum and diuretics |
WHO ATC |
|
0-L |
C02LL |
MAO inhibitors and diuretics |
WHO ATC |
|
0-L |
C02LL01 |
pargyline and diuretics |
WHO ATC |
|
0-L |
C02LN |
Serotonin antagonists and diuretics |
WHO ATC |
|
0-L |
C02LX |
Other antihypertensives and diuretics |
WHO ATC |
|
0-L |
C02LX01 |
pinacidil and diuretics |
WHO ATC |
|
0-L |
C02N |
COMBINATIONS OF ANTIHYPERTENSIVES IN ATC-GR. C02 |
WHO ATC |
|
0-L |
C03 |
DIURETICS |
WHO ATC |
|
0-L |
C03A |
LOW-CEILING DIURETICS, THIAZIDES |
WHO ATC |
|
0-L |
C03AA |
Thiazides, plain |
WHO ATC |
|
0-L |
C03AA01 |
bendroflumethiazide |
WHO ATC |
|
0-L |
C03AA02 |
hydroflumethiazide |
WHO ATC |
|
0-L |
C03AA03 |
hydrochlorothiazide |
WHO ATC |
|
0-L |
C03AA04 |
chlorothiazide |
WHO ATC |
|
0-L |
C03AA05 |
polythiazide |
WHO ATC |
|
0-L |
C03AA06 |
trichlormethiazide |
WHO ATC |
|
0-L |
C03AA07 |
cyclopenthiazide |
WHO ATC |
|
0-L |
C03AA08 |
methyclothiazide |
WHO ATC |
|
0-L |
C03AA09 |
cyclothiazide |
WHO ATC |
|
0-L |
C03AA13 |
mebutizide |
WHO ATC |
|
0-L |
C03AB |
Thiazides and potassium in combination |
WHO ATC |
|
0-L |
C03AB01 |
bendroflumethiazide and potassium |
WHO ATC |
|
0-L |
C03AB02 |
hydroflumethiazide and potassium |
WHO ATC |
|
0-L |
C03AB03 |
hydrochlorothiazide and potassium |
WHO ATC |
|
0-L |
C03AB04 |
chlorothiazide and potassium |
WHO ATC |
|
0-L |
C03AB05 |
polythiazide and potassium |
WHO ATC |
|
0-L |
C03AB06 |
trichlormethiazide and potassium |
WHO ATC |
|
0-L |
C03AB07 |
cyclopenthiazide and potassium |
WHO ATC |
|
0-L |
C03AB08 |
methyclothiazide and potassium |
WHO ATC |
|
0-L |
C03AB09 |
cyclothiazide and potassium |
WHO ATC |
|
0-L |
C03AH |
Thiazides, combinations with psycholeptics and/or analgesics |
WHO ATC |
|
0-L |
C03AH01 |
chlorothiazide, combinations |
WHO ATC |
|
0-L |
C03AH02 |
hydroflumethiazide, combinations |
WHO ATC |
|
0-L |
C03AX |
Thiazides, combinations with other drugs |
WHO ATC |
|
0-L |
C03AX01 |
hydrochlorothiazide, combinations |
WHO ATC |
|
0-L |
C03B |
LOW-CEILING DIURETICS, EXCL. THIAZIDES |
WHO ATC |
|
0-L |
C03BA |
Sulfonamides, plain |
WHO ATC |
|
0-L |
C03BA02 |
quinethazone |
WHO ATC |
|
0-L |
C03BA03 |
clopamide |
WHO ATC |
|
0-L |
C03BA04 |
chlortalidone |
WHO ATC |
|
0-L |
C03BA05 |
mefruside |
WHO ATC |
|
0-L |
C03BA07 |
clofenamide |
WHO ATC |
|
0-L |
C03BA08 |
metolazone |
WHO ATC |
|
0-L |
C03BA09 |
meticrane |
WHO ATC |
|
0-L |
C03BA10 |
xipamide |
WHO ATC |
|
0-L |
C03BA11 |
indapamide |
WHO ATC |
|
0-L |
C03BA12 |
clorexolone |
WHO ATC |
|
0-L |
C03BA13 |
fenquizone |
WHO ATC |
|
0-L |
C03BA82 |
clorexolone, comb. with psycholeptics |
WHO ATC |
|
0-L |
C03BB |
Sulfonamides and potassium in combination |
WHO ATC |
|
0-L |
C03BB02 |
quinethazone and potassium |
WHO ATC |
|
0-L |
C03BB03 |
clopamide and potassium |
WHO ATC |
|
0-L |
C03BB04 |
chlortalidone and potassium |
WHO ATC |
|
0-L |
C03BB05 |
mefruside and potassium |
WHO ATC |
|
0-L |
C03BB07 |
clofenamide and potassium |
WHO ATC |
|
0-L |
C03BC |
Mercurial diuretics |
WHO ATC |
|
0-L |
C03BC01 |
mersalyl |
WHO ATC |
|
0-L |
C03BD |
Xanthine derivatives |
WHO ATC |
|
0-L |
C03BD01 |
theobromine |
WHO ATC |
|
0-L |
C03BK |
Sulfonamides, combinations with other drugs |
WHO ATC |
|
0-L |
C03BX |
Other low-ceiling diuretics |
WHO ATC |
|
0-L |
C03BX03 |
cicletanine |
WHO ATC |
|
0-L |
C03C |
HIGH-CEILING DIURETICS |
WHO ATC |
|
0-L |
C03CA |
Sulfonamides, plain |
WHO ATC |
|
0-L |
C03CA01 |
furosemide |
WHO ATC |
|
0-L |
C03CA02 |
bumetanide |
WHO ATC |
|
0-L |
C03CA03 |
piretanide |
WHO ATC |
|
0-L |
C03CA04 |
torasemide |
WHO ATC |
|
0-L |
C03CB |
Sulfonamides and potassium in combination |
WHO ATC |
|
0-L |
C03CB01 |
furosemide and potassium |
WHO ATC |
|
0-L |
C03CB02 |
bumetanide and potassium |
WHO ATC |
|
0-L |
C03CC |
Aryloxyacetic acid derivatives |
WHO ATC |
|
0-L |
C03CC01 |
etacrynic acid |
WHO ATC |
|
0-L |
C03CC02 |
tienilic acid |
WHO ATC |
|
0-L |
C03CD |
Pyrazolone derivatives |
WHO ATC |
|
0-L |
C03CD01 |
muzolimine |
WHO ATC |
|
0-L |
C03CX |
Other high-ceiling diuretics |
WHO ATC |
|
0-L |
C03CX01 |
etozolin |
WHO ATC |
|
0-L |
C03D |
POTASSIUM-SPARING AGENTS |
WHO ATC |
|
0-L |
C03DA |
Aldosterone antagonists |
WHO ATC |
|
0-L |
C03DA01 |
spironolactone |
WHO ATC |
|
0-L |
C03DA02 |
potassium canrenoate |
WHO ATC |
|
0-L |
C03DA03 |
canrenone |
WHO ATC |
|
0-L |
C03DA04 |
eplerenone |
WHO ATC |
|
0-L |
C03DB |
Other potassium-sparing agents |
WHO ATC |
|
0-L |
C03DB01 |
amiloride |
WHO ATC |
|
0-L |
C03DB02 |
triamterene |
WHO ATC |
|
0-L |
C03E |
DIURETICS AND POTASSIUM-SPARING AGENTS IN COMBINATION |
WHO ATC |
|
0-L |
C03EA |
Low-ceiling diuretics and potassium-sparing agents |
WHO ATC |
|
0-L |
C03EA01 |
hydrochlorothiazide and potassium-sparing agents |
WHO ATC |
|
0-L |
C03EA02 |
trichlormethiazide and potassium-sparing agents |
WHO ATC |
|
0-L |
C03EA03 |
epitizide and potassium-sparing agents |
WHO ATC |
|
0-L |
C03EA04 |
altizide and potassium-sparing agents |
WHO ATC |
|
0-L |
C03EA05 |
mebutizide and potassium-sparing agents |
WHO ATC |
|
0-L |
C03EA06 |
chlortalidone and potassium-sparing agents |
WHO ATC |
|
0-L |
C03EA07 |
cyclopenthiazide and potassium-sparing agents |
WHO ATC |
|
0-L |
C03EA12 |
metolazone and potassium-sparing agents |
WHO ATC |
|
0-L |
C03EA13 |
bendroflumethiazide and potassium-sparing agents |
WHO ATC |
|
0-L |
C03EA14 |
butizide and potassium-sparing agents |
WHO ATC |
|
0-L |
C03EB |
High-ceiling diuretics and potassium-sparing agents |
WHO ATC |
|
0-L |
C03EB01 |
furosemide and potassium-sparing agents |
WHO ATC |
|
0-L |
C03EB02 |
bumetanide and potassium-sparing agents |
WHO ATC |
|
0-L |
C03X |
OTHER DIURETICS |
WHO ATC |
|
0-L |
C03XA |
Vasopressin antagonists |
WHO ATC |
|
0-L |
C03XA01 |
tolvaptan |
WHO ATC |
|
0-L |
C03XA02 |
conivaptan |
WHO ATC |
|
0-L |
C04 |
PERIPHERAL VASODILATORS |
WHO ATC |
|
0-L |
C04A |
PERIPHERAL VASODILATORS |
WHO ATC |
|
0-L |
C04AA |
2-amino-1-phenylethanol derivatives |
WHO ATC |
|
0-L |
C04AA01 |
isoxsuprine |
WHO ATC |
|
0-L |
C04AA02 |
buphenine |
WHO ATC |
|
0-L |
C04AA31 |
bamethan |
WHO ATC |
|
0-L |
C04AB |
Imidazoline derivatives |
WHO ATC |
|
0-L |
C04AB01 |
phentolamine |
WHO ATC |
|
0-L |
C04AB02 |
tolazoline |
WHO ATC |
|
0-L |
C04AC |
Nicotinic acid and derivatives |
WHO ATC |
|
0-L |
C04AC01 |
nicotinic acid |
WHO ATC |
|
0-L |
C04AC02 |
nicotinyl alcohol (pyridylcarbinol) |
WHO ATC |
|
0-L |
C04AC03 |
inositol nicotinate |
WHO ATC |
|
0-L |
C04AC07 |
ciclonicate |
WHO ATC |
|
0-L |
C04AD |
Purine derivatives |
WHO ATC |
|
0-L |
C04AD01 |
pentifylline |
WHO ATC |
|
0-L |
C04AD02 |
xantinol nicotinate |
WHO ATC |
|
0-L |
C04AD03 |
pentoxifylline |
WHO ATC |
|
0-L |
C04AD04 |
etofylline nicotinate |
WHO ATC |
|
0-L |
C04AE |
Ergot alkaloids |
WHO ATC |
|
0-L |
C04AE01 |
ergoloid mesylates |
WHO ATC |
|
0-L |
C04AE02 |
nicergoline |
WHO ATC |
|
0-L |
C04AE04 |
dihydroergocristine |
WHO ATC |
|
0-L |
C04AE51 |
ergoloid mesylates, combinations |
WHO ATC |
|
0-L |
C04AE54 |
dihydroergocristine, combinations |
WHO ATC |
|
0-L |
C04AF |
Enzymes |
WHO ATC |
|
0-L |
C04AF01 |
kallidinogenase |
WHO ATC |
|
0-L |
C04AX |
Other peripheral vasodilators |
WHO ATC |
|
0-L |
C04AX01 |
cyclandelate |
WHO ATC |
|
0-L |
C04AX02 |
phenoxybenzamine |
WHO ATC |
|
0-L |
C04AX07 |
vincamine |
WHO ATC |
|
0-L |
C04AX10 |
moxisylyte |
WHO ATC |
|
0-L |
C04AX11 |
bencyclane |
WHO ATC |
|
0-L |
C04AX17 |
vinburnine |
WHO ATC |
|
0-L |
C04AX19 |
suloctidil |
WHO ATC |
|
0-L |
C04AX20 |
buflomedil |
WHO ATC |
|
0-L |
C04AX21 |
naftidrofuryl |
WHO ATC |
|
0-L |
C04AX23 |
butalamine |
WHO ATC |
|
0-L |
C04AX24 |
visnadine |
WHO ATC |
|
0-L |
C04AX26 |
cetiedil |
WHO ATC |
|
0-L |
C04AX27 |
cinepazide |
WHO ATC |
|
0-L |
C04AX28 |
ifenprodil |
WHO ATC |
|
0-L |
C04AX30 |
azapetine |
WHO ATC |
|
0-L |
C04AX32 |
fasudil |
WHO ATC |
|
0-L |
C05 |
VASOPROTECTIVES |
WHO ATC |
|
0-L |
C05A |
AGENTS FOR TREATMENT OF HEMORRHOIDS AND ANALFISSURES FOR TOPICAL USE |
WHO ATC |
|
0-L |
C05AA |
Corticosteroids |
WHO ATC |
|
0-L |
C05AA01 |
hydrocortisone |
WHO ATC |
|
0-L |
C05AA04 |
prednisolone |
WHO ATC |
|
0-L |
C05AA05 |
betamethasone |
WHO ATC |
|
0-L |
C05AA06 |
fluorometholone |
WHO ATC |
|
0-L |
C05AA08 |
fluocortolone |
WHO ATC |
|
0-L |
C05AA09 |
dexamethasone |
WHO ATC |
|
0-L |
C05AA10 |
fluocinolone acetonide |
WHO ATC |
|
0-L |
C05AA11 |
fluocinonide |
WHO ATC |
|
0-L |
C05AB |
Antibiotics |
WHO ATC |
|
0-L |
C05AD |
Local anesthetics |
WHO ATC |
|
0-L |
C05AD01 |
lidocaine |
WHO ATC |
|
0-L |
C05AD02 |
tetracaine |
WHO ATC |
|
0-L |
C05AD03 |
benzocaine |
WHO ATC |
|
0-L |
C05AD04 |
cinchocaine |
WHO ATC |
|
0-L |
C05AD05 |
procaine |
WHO ATC |
|
0-L |
C05AD06 |
oxetacaine |
WHO ATC |
|
0-L |
C05AD07 |
pramocaine |
WHO ATC |
|
0-L |
C05AE |
Muscle relaxants |
WHO ATC |
|
0-L |
C05AE01 |
glyceryl trinitrate |
WHO ATC |
|
0-L |
C05AE02 |
isosorbide dinitrate |
WHO ATC |
|
0-L |
C05AX |
Other agents for treatment of hemorrhoids and anal fissures for topical use |
WHO ATC |
|
0-L |
C05AX01 |
aluminium preparations |
WHO ATC |
|
0-L |
C05AX02 |
bismuth preparations, combinations |
WHO ATC |
|
0-L |
C05AX03 |
other preparations, combinations |
WHO ATC |
|
0-L |
C05AX04 |
zinc preparations |
WHO ATC |
|
0-L |
C05AX05 |
tribenoside |
WHO ATC |
|
0-L |
C05B |
ANTIVARICOSE THERAPY |
WHO ATC |
|
0-L |
C05BA |
Heparins or heparinoids for topical use |
WHO ATC |
|
0-L |
C05BA01 |
organo-heparinoid |
WHO ATC |
|
0-L |
C05BA02 |
sodium apolate |
WHO ATC |
|
0-L |
C05BA03 |
heparin |
WHO ATC |
|
0-L |
C05BA04 |
pentosan polysulfate sodium |
WHO ATC |
|
0-L |
C05BA51 |
heparinoid, combinations |
WHO ATC |
|
0-L |
C05BA53 |
heparin, combinations |
WHO ATC |
|
0-L |
C05BB |
Sclerosing agents for local injection |
WHO ATC |
|
0-L |
C05BB01 |
monoethanolamine oleate |
WHO ATC |
|
0-L |
C05BB02 |
polidocanol |
WHO ATC |
|
0-L |
C05BB03 |
invert sugar |
WHO ATC |
|
0-L |
C05BB04 |
sodium tetradecyl sulfate |
WHO ATC |
|
0-L |
C05BB05 |
phenol |
WHO ATC |
|
0-L |
C05BB56 |
glucose, combinations |
WHO ATC |
|
0-L |
C05BX |
Other sclerosing agents |
WHO ATC |
|
0-L |
C05BX01 |
calcium dobesilate |
WHO ATC |
|
0-L |
C05BX51 |
calcium dobesilate, combinations |
WHO ATC |
|
0-L |
C05C |
CAPILLARY STABILIZING AGENTS |
WHO ATC |
|
0-L |
C05CA |
Bioflavonoids |
WHO ATC |
|
0-L |
C05CA01 |
rutoside |
WHO ATC |
|
0-L |
C05CA02 |
monoxerutin |
WHO ATC |
|
0-L |
C05CA03 |
diosmin |
WHO ATC |
|
0-L |
C05CA04 |
troxerutin |
WHO ATC |
|
0-L |
C05CA05 |
hidrosmin |
WHO ATC |
|
0-L |
C05CA51 |
rutoside, combinations |
WHO ATC |
|
0-L |
C05CA53 |
diosmin, combinations |
WHO ATC |
|
0-L |
C05CA54 |
troxerutin, combinations |
WHO ATC |
|
0-L |
C05CX |
Other capillary stabilizing agents |
WHO ATC |
|
0-L |
C05CX01 |
tribenoside |
WHO ATC |
|
0-L |
C07 |
BETA BLOCKING AGENTS |
WHO ATC |
|
0-L |
C07A |
BETA BLOCKING AGENTS |
WHO ATC |
|
0-L |
C07AA |
Beta blocking agents, non-selective |
WHO ATC |
|
0-L |
C07AA01 |
alprenolol |
WHO ATC |
|
0-L |
C07AA02 |
oxprenolol |
WHO ATC |
|
0-L |
C07AA03 |
pindolol |
WHO ATC |
|
0-L |
C07AA05 |
propranolol |
WHO ATC |
|
0-L |
C07AA06 |
timolol |
WHO ATC |
|
0-L |
C07AA07 |
sotalol |
WHO ATC |
|
0-L |
C07AA12 |
nadolol |
WHO ATC |
|
0-L |
C07AA14 |
mepindolol |
WHO ATC |
|
0-L |
C07AA15 |
carteolol |
WHO ATC |
|
0-L |
C07AA16 |
tertatolol |
WHO ATC |
|
0-L |
C07AA17 |
bopindolol |
WHO ATC |
|
0-L |
C07AA19 |
bupranolol |
WHO ATC |
|
0-L |
C07AA23 |
penbutolol |
WHO ATC |
|
0-L |
C07AA27 |
cloranolol |
WHO ATC |
|
0-L |
C07AA57 |
sotalol, combinations |
WHO ATC |
|
0-L |
C07AB |
Beta blocking agents, selective |
WHO ATC |
|
0-L |
C07AB01 |
practolol |
WHO ATC |
|
0-L |
C07AB02 |
metoprolol |
WHO ATC |
|
0-L |
C07AB03 |
atenolol |
WHO ATC |
|
0-L |
C07AB04 |
acebutolol |
WHO ATC |
|
0-L |
C07AB05 |
betaxolol |
WHO ATC |
|
0-L |
C07AB06 |
bevantolol |
WHO ATC |
|
0-L |
C07AB07 |
bisoprolol |
WHO ATC |
|
0-L |
C07AB08 |
celiprolol |
WHO ATC |
|
0-L |
C07AB09 |
esmolol |
WHO ATC |
|
0-L |
C07AB10 |
epanolol |
WHO ATC |
|
0-L |
C07AB11 |
s-atenolol |
WHO ATC |
|
0-L |
C07AB12 |
nebivolol |
WHO ATC |
|
0-L |
C07AB13 |
talinolol |
WHO ATC |
|
0-L |
C07AB52 |
metoprolol, combinations |
WHO ATC |
|
0-L |
C07AB57 |
bisoprolol, combinations |
WHO ATC |
|
0-L |
C07AG |
Alpha and beta blocking agents |
WHO ATC |
|
0-L |
C07AG01 |
labetalol |
WHO ATC |
|
0-L |
C07AG02 |
carvedilol |
WHO ATC |
|
0-L |
C07B |
BETA BLOCKING AGENTS AND THIAZIDES |
WHO ATC |
|
0-L |
C07BA |
Beta blocking agents, non-selective, and thiazides |
WHO ATC |
|
0-L |
C07BA02 |
oxprenolol and thiazides |
WHO ATC |
|
0-L |
C07BA05 |
propranolol and thiazides |
WHO ATC |
|
0-L |
C07BA06 |
timolol and thiazides |
WHO ATC |
|
0-L |
C07BA07 |
sotalol and thiazides |
WHO ATC |
|
0-L |
C07BA12 |
nadolol and thiazides |
WHO ATC |
|
0-L |
C07BA68 |
metipranolol and thiazides, combinations |
WHO ATC |
|
0-L |
C07BB |
Beta blocking agents, selective, and thiazides |
WHO ATC |
|
0-L |
C07BB02 |
metoprolol and thiazides |
WHO ATC |
|
0-L |
C07BB03 |
atenolol and thiazides |
WHO ATC |
|
0-L |
C07BB04 |
acebutolol and thiazides |
WHO ATC |
|
0-L |
C07BB06 |
bevantolol and thiazides |
WHO ATC |
|
0-L |
C07BB07 |
bisoprolol and thiazides |
WHO ATC |
|
0-L |
C07BB52 |
metoprolol and thiazides, combinations |
WHO ATC |
|
0-L |
C07BG |
Alpha and beta blocking agents and thiazides |
WHO ATC |
|
0-L |
C07BG01 |
labetalol and thiazides |
WHO ATC |
|
0-L |
C07C |
BETA BLOCKING AGENTS AND OTHER DIURETICS |
WHO ATC |
|
0-L |
C07CA |
Beta blocking agents, non-selective, and other diuretics |
WHO ATC |
|
0-L |
C07CA02 |
oxprenolol and other diuretics |
WHO ATC |
|
0-L |
C07CA03 |
pindolol and other diuretics |
WHO ATC |
|
0-L |
C07CA17 |
bopindolol and other diuretics |
WHO ATC |
|
0-L |
C07CA23 |
penbutolol and other diuretics |
WHO ATC |
|
0-L |
C07CB |
Beta blocking agents, selective, and other diuretics |
WHO ATC |
|
0-L |
C07CB02 |
metoprolol and other diuretics |
WHO ATC |
|
0-L |
C07CB03 |
atenolol and other diuretics |
WHO ATC |
|
0-L |
C07CB53 |
atenolol and other diuretics, combinations |
WHO ATC |
|
0-L |
C07CG |
Alpha and beta blocking agents and other diuretics |
WHO ATC |
|
0-L |
C07CG01 |
labetalol and other diuretics |
WHO ATC |
|
0-L |
C07D |
BETA BLOCKING AGENTS, THIAZIDES AND OTHER DIURETICS |
WHO ATC |
|
0-L |
C07DA |
Beta blocking agents, non-selective, thiazides and other diuretics |
WHO ATC |
|
0-L |
C07DA06 |
timolol, thiazides and other diuretics |
WHO ATC |
|
0-L |
C07DB |
Beta blocking agents, selective, thiazides and other diuretics |
WHO ATC |
|
0-L |
C07DB01 |
atenolol, thiazides and other diuretics |
WHO ATC |
|
0-L |
C07E |
BETA BLOCKING AGENTS AND VASODILATORS |
WHO ATC |
|
0-L |
C07EA |
Beta blocking agents, non-selective, and vasodilators |
WHO ATC |
|
0-L |
C07EB |
Beta blocking agents, selective, and vasodilators |
WHO ATC |
|
0-L |
C07F |
BETA BLOCKING AGENTS AND OTHER ANTIHYPERTENSIVES |
WHO ATC |
|
0-L |
C07FA |
Beta blocking agents, non-selective, and other antihypertensives |
WHO ATC |
|
0-L |
C07FA05 |
propranolol and other antihypertensives |
WHO ATC |
|
0-L |
C07FB |
Beta blocking agents, selective, and other antihypertensives |
WHO ATC |
|
0-L |
C07FB02 |
metoprolol and other antihypertensives |
WHO ATC |
|
0-L |
C07FB03 |
atenolol and other antihypertensives |
WHO ATC |
|
0-L |
C08 |
CALCIUM CHANNEL BLOCKERS |
WHO ATC |
|
0-L |
C08C |
SELECTIVE CALCIUM CHANNEL BLOCKERS WITH MAINLY VASCULAR EFFECTS |
WHO ATC |
|
0-L |
C08CA |
Dihydropyridine derivatives |
WHO ATC |
|
0-L |
C08CA01 |
amlodipine |
WHO ATC |
|
0-L |
C08CA02 |
felodipine |
WHO ATC |
|
0-L |
C08CA03 |
isradipine |
WHO ATC |
|
0-L |
C08CA04 |
nicardipine |
WHO ATC |
|
0-L |
C08CA05 |
nifedipine |
WHO ATC |
|
0-L |
C08CA06 |
nimodipine |
WHO ATC |
|
0-L |
C08CA07 |
nisoldipine |
WHO ATC |
|
0-L |
C08CA08 |
nitrendipine |
WHO ATC |
|
0-L |
C08CA09 |
lacidipine |
WHO ATC |
|
0-L |
C08CA10 |
nilvadipine |
WHO ATC |
|
0-L |
C08CA11 |
manidipine |
WHO ATC |
|
0-L |
C08CA12 |
barnidipine |
WHO ATC |
|
0-L |
C08CA13 |
lercanidipine |
WHO ATC |
|
0-L |
C08CA14 |
cilnidipine |
WHO ATC |
|
0-L |
C08CA15 |
benidipine |
WHO ATC |
|
0-L |
C08CA55 |
nifedipine, combinations |
WHO ATC |
|
0-L |
C08CX |
Other selective calcium channel blockers with mainly vascular effects |
WHO ATC |
|
0-L |
C08CX01 |
mibefradil |
WHO ATC |
|
0-L |
C08D |
SELECTIVE CALCIUM CHANNEL BLOCKERS WITH DIRECT CARDIAC EFFECTS |
WHO ATC |
|
0-L |
C08DA |
Phenylalkylamine derivatives |
WHO ATC |
|
0-L |
C08DA01 |
verapamil |
WHO ATC |
|
0-L |
C08DA02 |
gallopamil |
WHO ATC |
|
0-L |
C08DA51 |
verapamil, combinations |
WHO ATC |
|
0-L |
C08DB |
Benzothiazepine derivatives |
WHO ATC |
|
0-L |
C08DB01 |
diltiazem |
WHO ATC |
|
0-L |
C08E |
NON-SELECTIVE CALCIUM CHANNEL BLOCKERS |
WHO ATC |
|
0-L |
C08EA |
Phenylalkylamine derivatives |
WHO ATC |
|
0-L |
C08EA01 |
fendiline |
WHO ATC |
|
0-L |
C08EA02 |
bepridil |
WHO ATC |
|
0-L |
C08EX |
Other non-selective calcium channel blockers |
WHO ATC |
|
0-L |
C08EX01 |
lidoflazine |
WHO ATC |
|
0-L |
C08EX02 |
perhexiline |
WHO ATC |
|
0-L |
C08G |
CALCIUM CHANNEL BLOCKERS AND DIURETICS |
WHO ATC |
|
0-L |
C08GA |
Calcium channel blockers and diuretics |
WHO ATC |
|
0-L |
C08GA01 |
nifedipine and diuretics |
WHO ATC |
|
0-L |
C09 |
AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM |
WHO ATC |
|
0-L |
C09A |
ACE INHIBITORS, PLAIN |
WHO ATC |
|
0-L |
C09AA |
ACE inhibitors, plain |
WHO ATC |
|
0-L |
C09AA01 |
captopril |
WHO ATC |
|
0-L |
C09AA02 |
enalapril |
WHO ATC |
|
0-L |
C09AA03 |
lisinopril |
WHO ATC |
|
0-L |
C09AA04 |
perindopril |
WHO ATC |
|
0-L |
C09AA05 |
ramipril |
WHO ATC |
|
0-L |
C09AA06 |
quinapril |
WHO ATC |
|
0-L |
C09AA07 |
benazepril |
WHO ATC |
|
0-L |
C09AA08 |
cilazapril |
WHO ATC |
|
0-L |
C09AA09 |
fosinopril |
WHO ATC |
|
0-L |
C09AA10 |
trandolapril |
WHO ATC |
|
0-L |
C09AA11 |
spirapril |
WHO ATC |
|
0-L |
C09AA12 |
delapril |
WHO ATC |
|
0-L |
C09AA13 |
moexipril |
WHO ATC |
|
0-L |
C09AA14 |
temocapril |
WHO ATC |
|
0-L |
C09AA15 |
zofenopril |
WHO ATC |
|
0-L |
C09AA16 |
imidapril |
WHO ATC |
|
0-L |
C09B |
ACE INHIBITORS, COMBINATIONS |
WHO ATC |
|
0-L |
C09BA |
ACE inhibitors and diuretics |
WHO ATC |
|
0-L |
C09BA01 |
captopril and diuretics |
WHO ATC |
|
0-L |
C09BA02 |
enalapril and diuretics |
WHO ATC |
|
0-L |
C09BA03 |
lisinopril and diuretics |
WHO ATC |
|
0-L |
C09BA04 |
perindopril and diuretics |
WHO ATC |
|
0-L |
C09BA05 |
ramipril and diuretics |
WHO ATC |
|
0-L |
C09BA06 |
quinapril and diuretics |
WHO ATC |
|
0-L |
C09BA07 |
benazepril and diuretics |
WHO ATC |
|
0-L |
C09BA08 |
cilazapril and diuretics |
WHO ATC |
|
0-L |
C09BA09 |
fosinopril and diuretics |
WHO ATC |
|
0-L |
C09BA12 |
delapril and diuretics |
WHO ATC |
|
0-L |
C09BA13 |
moexipril and diuretics |
WHO ATC |
|
0-L |
C09BA15 |
zofenopril and diuretics |
WHO ATC |
|
0-L |
C09BB |
ACE inhibitors and calcium channel blockers |
WHO ATC |
|
0-L |
C09BB02 |
enalapril and lercanidipine |
WHO ATC |
|
0-L |
C09BB03 |
lisinopril and amlodipine |
WHO ATC |
|
0-L |
C09BB04 |
perindopril and amlodipine |
WHO ATC |
|
0-L |
C09BB05 |
ramipril and felodipine |
WHO ATC |
|
0-L |
C09BB10 |
trandolapril and verapamil |
WHO ATC |
|
0-L |
C09BB12 |
delapril and manidipine |
WHO ATC |
|
0-L |
C09C |
ANGIOTENSIN II ANTAGONISTS, PLAIN |
WHO ATC |
|
0-L |
C09CA |
Angiotensin II antagonists, plain |
WHO ATC |
|
0-L |
C09CA01 |
losartan |
WHO ATC |
|
0-L |
C09CA02 |
eprosartan |
WHO ATC |
|
0-L |
C09CA03 |
valsartan |
WHO ATC |
|
0-L |
C09CA04 |
irbesartan |
WHO ATC |
|
0-L |
C09CA05 |
tasosartan |
WHO ATC |
|
0-L |
C09CA06 |
candesartan |
WHO ATC |
|
0-L |
C09CA07 |
telmisartan |
WHO ATC |
|
0-L |
C09CA08 |
olmesartan medoxomil |
WHO ATC |
|
0-L |
C09D |
ANGIOTENSIN II ANTAGONISTS, COMBINATIONS |
WHO ATC |
|
0-L |
C09DA |
Angiotensin II antagonists and diuretics |
WHO ATC |
|
0-L |
C09DA01 |
losartan and diuretics |
WHO ATC |
|
0-L |
C09DA02 |
eprosartan and diuretics |
WHO ATC |
|
0-L |
C09DA03 |
valsartan and diuretics |
WHO ATC |
|
0-L |
C09DA04 |
irbesartan and diuretics |
WHO ATC |
|
0-L |
C09DA06 |
candesartan and diuretics |
WHO ATC |
|
0-L |
C09DA07 |
telmisartan and diuretics |
WHO ATC |
|
0-L |
C09DA08 |
olmesartan medoxomil and diuretics |
WHO ATC |
|
0-L |
C09DB |
Angiotensin II antagonists and calcium channel blockers |
WHO ATC |
|
0-L |
C09DB01 |
valsartan and amlodipine |
WHO ATC |
|
0-L |
C09DB02 |
olmesartan medoxomil and amlodipine |
WHO ATC |
|
0-L |
C09DB04 |
telmisartan and amlodipine |
WHO ATC |
|
0-L |
C09DX |
Angiotensin II antagonists, other combinations |
WHO ATC |
|
0-L |
C09DX01 |
valsartan, amlodipine and hydrochlorothiazide |
WHO ATC |
|
0-L |
C09DX02 |
valsartan and aliskiren |
WHO ATC |
|
0-L |
C09X |
OTHER AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM |
WHO ATC |
|
0-L |
C09XA |
Renin-inhibitors |
WHO ATC |
|
0-L |
C09XA01 |
remikiren |
WHO ATC |
|
0-L |
C09XA02 |
aliskiren |
WHO ATC |
|
0-L |
C09XA52 |
aliskiren and hydrochlorothiazide |
WHO ATC |
|
0-L |
C10 |
LIPID MODIFYING AGENTS |
WHO ATC |
|
0-L |
C10A |
LIPID MODIFYING AGENTS, PLAIN |
WHO ATC |
|
0-L |
C10AA |
HMG CoA reductase inhibitors |
WHO ATC |
|
0-L |
C10AA01 |
simvastatin |
WHO ATC |
|
0-L |
C10AA02 |
lovastatin |
WHO ATC |
|
0-L |
C10AA03 |
pravastatin |
WHO ATC |
|
0-L |
C10AA04 |
fluvastatin |
WHO ATC |
|
0-L |
C10AA05 |
atorvastatin |
WHO ATC |
|
0-L |
C10AA06 |
cerivastatin |
WHO ATC |
|
0-L |
C10AA07 |
rosuvastatin |
WHO ATC |
|
0-L |
C10AA08 |
pitavastatin |
WHO ATC |
|
0-L |
C10AB |
Fibrates |
WHO ATC |
|
0-L |
C10AB01 |
clofibrate |
WHO ATC |
|
0-L |
C10AB02 |
bezafibrate |
WHO ATC |
|
0-L |
C10AB03 |
aluminium clofibrate |
WHO ATC |
|
0-L |
C10AB04 |
gemfibrozil |
WHO ATC |
|
0-L |
C10AB05 |
fenofibrate |
WHO ATC |
|
0-L |
C10AB06 |
simfibrate |
WHO ATC |
|
0-L |
C10AB07 |
ronifibrate |
WHO ATC |
|
0-L |
C10AB08 |
ciprofibrate |
WHO ATC |
|
0-L |
C10AB09 |
etofibrate |
WHO ATC |
|
0-L |
C10AB10 |
clofibride |
WHO ATC |
|
0-L |
C10AC |
Bile acid sequestrants |
WHO ATC |
|
0-L |
C10AC01 |
colestyramine |
WHO ATC |
|
0-L |
C10AC02 |
colestipol |
WHO ATC |
|
0-L |
C10AC03 |
colextran |
WHO ATC |
|
0-L |
C10AC04 |
colesevelam |
WHO ATC |
|
0-L |
C10AD |
Nicotinic acid and derivatives |
WHO ATC |
|
0-L |
C10AD01 |
niceritrol |
WHO ATC |
|
0-L |
C10AD02 |
nicotinic acid |
WHO ATC |
|
0-L |
C10AD03 |
nicofuranose |
WHO ATC |
|
0-L |
C10AD04 |
aluminium nicotinate |
WHO ATC |
|
0-L |
C10AD05 |
nicotinyl alcohol (pyridylcarbinol) |
WHO ATC |
|
0-L |
C10AD06 |
acipimox |
WHO ATC |
|
0-L |
C10AD52 |
nicotinic acid, combinations |
WHO ATC |
|
0-L |
C10AX |
Other lipid modifying agents |
WHO ATC |
|
0-L |
C10AX01 |
dextrothyroxine |
WHO ATC |
|
0-L |
C10AX02 |
probucol |
WHO ATC |
|
0-L |
C10AX03 |
tiadenol |
WHO ATC |
|
0-L |
C10AX05 |
meglutol |
WHO ATC |
|
0-L |
C10AX06 |
omega-3-triglycerides incl. other esters and acids |
WHO ATC |
|
0-L |
C10AX07 |
magnesium pyridoxal 5-phosphate glutamate |
WHO ATC |
|
0-L |
C10AX08 |
policosanol |
WHO ATC |
|
0-L |
C10AX09 |
ezetimibe |
WHO ATC |
|
0-L |
C10AX10 |
alipogene tiparvovec |
WHO ATC |
|
0-L |
C10B |
LIPID MODIFYING AGENTS, COMBINATIONS |
WHO ATC |
|
0-L |
C10BA |
HMG CoA reductase inhibitors in combination with other lipid modifying agents |
WHO ATC |
|
0-L |
C10BA01 |
lovastatin and nicotinic acid |
WHO ATC |
|
0-L |
C10BA02 |
simvastatin and ezetimibe |
WHO ATC |
|
0-L |
C10BA03 |
pravastatin and fenofibrate |
WHO ATC |
|
0-L |
C10BX |
HMG CoA reductase inhibitors, other combinations |
WHO ATC |
|
0-L |
C10BX01 |
simvastatin and acetylsalicylic acid |
WHO ATC |
|
0-L |
C10BX02 |
pravastatin and acetylsalicylic acid |
WHO ATC |
|
0-L |
C10BX03 |
atorvastatin and amlodipine |
WHO ATC |
|
0-L |
D |
DERMATOLOGICALS |
WHO ATC |
|
0-L |
D01 |
ANTIFUNGALS FOR DERMATOLOGICAL USE |
WHO ATC |
|
0-L |
D01A |
ANTIFUNGALS FOR TOPICAL USE |
WHO ATC |
|
0-L |
D01AA |
Antibiotics |
WHO ATC |
|
0-L |
D01AA01 |
nystatin |
WHO ATC |
|
0-L |
D01AA02 |
natamycin |
WHO ATC |
|
0-L |
D01AA03 |
hachimycin |
WHO ATC |
|
0-L |
D01AA04 |
pecilocin |
WHO ATC |
|
0-L |
D01AA06 |
mepartricin |
WHO ATC |
|
0-L |
D01AA07 |
pyrrolnitrin |
WHO ATC |
|
0-L |
D01AA08 |
griseofulvin |
WHO ATC |
|
0-L |
D01AA20 |
combinations |
WHO ATC |
|
0-L |
D01AC |
Imidazole and triazole derivatives |
WHO ATC |
|
0-L |
D01AC01 |
clotrimazole |
WHO ATC |
|
0-L |
D01AC02 |
miconazole |
WHO ATC |
|
0-L |
D01AC03 |
econazole |
WHO ATC |
|
0-L |
D01AC04 |
chlormidazole |
WHO ATC |
|
0-L |
D01AC05 |
isoconazole |
WHO ATC |
|
0-L |
D01AC06 |
tiabendazole |
WHO ATC |
|
0-L |
D01AC07 |
tioconazole |
WHO ATC |
|
0-L |
D01AC08 |
ketoconazole |
WHO ATC |
|
0-L |
D01AC09 |
sulconazole |
WHO ATC |
|
0-L |
D01AC10 |
bifonazole |
WHO ATC |
|
0-L |
D01AC11 |
oxiconazole |
WHO ATC |
|
0-L |
D01AC12 |
fenticonazole |
WHO ATC |
|
0-L |
D01AC13 |
omoconazole |
WHO ATC |
|
0-L |
D01AC14 |
sertaconazole |
WHO ATC |
|
0-L |
D01AC15 |
fluconazole |
WHO ATC |
|
0-L |
D01AC16 |
flutrimazole |
WHO ATC |
|
0-L |
D01AC20 |
combinations |
WHO ATC |
|
0-L |
D01AC52 |
miconazole, combinations |
WHO ATC |
|
0-L |
D01AC60 |
bifonazole, combinations |
WHO ATC |
|
0-L |
D01AE |
Other antifungals for topical use |
WHO ATC |
|
0-L |
D01AE01 |
bromochlorosalicylanilide |
WHO ATC |
|
0-L |
D01AE02 |
methylrosaniline |
WHO ATC |
|
0-L |
D01AE03 |
tribromometacresol |
WHO ATC |
|
0-L |
D01AE04 |
undecylenic acid |
WHO ATC |
|
0-L |
D01AE05 |
polynoxylin |
WHO ATC |
|
0-L |
D01AE06 |
2-(4-chlorphenoxy)-ethanol |
WHO ATC |
|
0-L |
D01AE07 |
chlorphenesin |
WHO ATC |
|
0-L |
D01AE08 |
ticlatone |
WHO ATC |
|
0-L |
D01AE09 |
sulbentine |
WHO ATC |
|
0-L |
D01AE10 |
ethyl hydroxybenzoate |
WHO ATC |
|
0-L |
D01AE11 |
haloprogin |
WHO ATC |
|
0-L |
D01AE12 |
salicylic acid |
WHO ATC |
|
0-L |
D01AE13 |
selenium sulfide |
WHO ATC |
|
0-L |
D01AE14 |
ciclopirox |
WHO ATC |
|
0-L |
D01AE15 |
terbinafine |
WHO ATC |
|
0-L |
D01AE16 |
amorolfine |
WHO ATC |
|
0-L |
D01AE17 |
dimazole |
WHO ATC |
|
0-L |
D01AE18 |
tolnaftate |
WHO ATC |
|
0-L |
D01AE19 |
tolciclate |
WHO ATC |
|
0-L |
D01AE20 |
combinations |
WHO ATC |
|
0-L |
D01AE21 |
flucytosine |
WHO ATC |
|
0-L |
D01AE22 |
naftifine |
WHO ATC |
|
0-L |
D01AE23 |
butenafine |
WHO ATC |
|
0-L |
D01AE54 |
undecylenic acid, combinations |
WHO ATC |
|
0-L |
D01B |
ANTIFUNGALS FOR SYSTEMIC USE |
WHO ATC |
|
0-L |
D01BA |
Antifungals for systemic use |
WHO ATC |
|
0-L |
D01BA01 |
griseofulvin |
WHO ATC |
|
0-L |
D01BA02 |
terbinafine |
WHO ATC |
|
0-L |
D02 |
EMOLLIENTS AND PROTECTIVES |
WHO ATC |
|
0-L |
D02A |
EMOLLIENTS AND PROTECTIVES |
WHO ATC |
|
0-L |
D02AA |
Silicone products |
WHO ATC |
|
0-L |
D02AB |
Zinc products |
WHO ATC |
|
0-L |
D02AC |
Soft paraffin and fat products |
WHO ATC |
|
0-L |
D02AD |
Liquid plasters |
WHO ATC |
|
0-L |
D02AE |
Carbamide products |
WHO ATC |
|
0-L |
D02AE01 |
carbamide |
WHO ATC |
|
0-L |
D02AE51 |
carbamide, combinations |
WHO ATC |
|
0-L |
D02AF |
Salicylic acid preparations |
WHO ATC |
|
0-L |
D02AX |
Other emollients and protectives |
WHO ATC |
|
0-L |
D02B |
PROTECTIVES AGAINST UV-RADIATION |
WHO ATC |
|
0-L |
D02BA |
Protectives against UV-radiation for topical use |
WHO ATC |
|
0-L |
D02BA01 |
aminobenzoic acid |
WHO ATC |
|
0-L |
D02BA02 |
octinoxate |
WHO ATC |
|
0-L |
D02BB |
Protectives against UV-radiation for systemic use |
WHO ATC |
|
0-L |
D02BB01 |
betacarotene |
WHO ATC |
|
0-L |
D03 |
PREPARATIONS FOR TREATMENT OF WOUNDS AND ULCERS |
WHO ATC |
|
0-L |
D03A |
CICATRIZANTS |
WHO ATC |
|
0-L |
D03AA |
Cod-liver oil ointments |
WHO ATC |
|
0-L |
D03AX |
Other cicatrizants |
WHO ATC |
|
0-L |
D03AX01 |
cadexomer iodine |
WHO ATC |
|
0-L |
D03AX02 |
dextranomer |
WHO ATC |
|
0-L |
D03AX03 |
dexpanthenol |
WHO ATC |
|
0-L |
D03AX04 |
calcium pantothenate |
WHO ATC |
|
0-L |
D03AX05 |
hyaluronic acid |
WHO ATC |
|
0-L |
D03AX06 |
becaplermin |
WHO ATC |
|
0-L |
D03AX09 |
crilanomer |
WHO ATC |
|
0-L |
D03AX10 |
enoxolone |
WHO ATC |
|
0-L |
D03B |
ENZYMES |
WHO ATC |
|
0-L |
D03BA |
Proteolytic enzymes |
WHO ATC |
|
0-L |
D03BA01 |
trypsin |
WHO ATC |
|
0-L |
D03BA02 |
collagenase |
WHO ATC |
|
0-L |
D03BA52 |
collagenase, combinations |
WHO ATC |
|
0-L |
D04 |
ANTIPRURITICS, INCL. ANTIHISTAMINES, ANESTHETICS, ETC. |
WHO ATC |
|
0-L |
D04A |
ANTIPRURITICS, INCL. ANTIHISTAMINES, ANESTHETICS, ETC. |
WHO ATC |
|
0-L |
D04AA |
Antihistamines for topical use |
WHO ATC |
|
0-L |
D04AA01 |
thonzylamine |
WHO ATC |
|
0-L |
D04AA02 |
mepyramine |
WHO ATC |
|
0-L |
D04AA03 |
thenalidine |
WHO ATC |
|
0-L |
D04AA04 |
tripelennamine |
WHO ATC |
|
0-L |
D04AA09 |
chloropyramine |
WHO ATC |
|
0-L |
D04AA10 |
promethazine |
WHO ATC |
|
0-L |
D04AA12 |
tolpropamine |
WHO ATC |
|
0-L |
D04AA13 |
dimetindene |
WHO ATC |
|
0-L |
D04AA14 |
clemastine |
WHO ATC |
|
0-L |
D04AA15 |
bamipine |
WHO ATC |
|
0-L |
D04AA22 |
isothipendyl |
WHO ATC |
|
0-L |
D04AA32 |
diphenhydramine |
WHO ATC |
|
0-L |
D04AA33 |
diphenhydramine methylbromide |
WHO ATC |
|
0-L |
D04AA34 |
chlorphenoxamine |
WHO ATC |
|
0-L |
D04AB |
Anesthetics for topical use |
WHO ATC |
|
0-L |
D04AB01 |
lidocaine |
WHO ATC |
|
0-L |
D04AB02 |
cinchocaine |
WHO ATC |
|
0-L |
D04AB03 |
oxybuprocaine |
WHO ATC |
|
0-L |
D04AB04 |
benzocaine |
WHO ATC |
|
0-L |
D04AB05 |
quinisocaine |
WHO ATC |
|
0-L |
D04AB06 |
tetracaine |
WHO ATC |
|
0-L |
D04AB07 |
pramocaine |
WHO ATC |
|
0-L |
D04AX |
Other antipruritics |
WHO ATC |
|
0-L |
D05 |
ANTIPSORIATICS |
WHO ATC |
|
0-L |
D05A |
ANTIPSORIATICS FOR TOPICAL USE |
WHO ATC |
|
0-L |
D05AA |
Tars |
WHO ATC |
|
0-L |
D05AC |
Antracen derivatives |
WHO ATC |
|
0-L |
D05AC01 |
dithranol |
WHO ATC |
|
0-L |
D05AC51 |
dithranol, combinations |
WHO ATC |
|
0-L |
D05AD |
Psoralens for topical use |
WHO ATC |
|
0-L |
D05AD01 |
trioxysalen |
WHO ATC |
|
0-L |
D05AD02 |
methoxsalen |
WHO ATC |
|
0-L |
D05AX |
Other antipsoriatics for topical use |
WHO ATC |
|
0-L |
D05AX01 |
fumaric acid |
WHO ATC |
|
0-L |
D05AX02 |
calcipotriol |
WHO ATC |
|
0-L |
D05AX03 |
calcitriol |
WHO ATC |
|
0-L |
D05AX04 |
tacalcitol |
WHO ATC |
|
0-L |
D05AX05 |
tazarotene |
WHO ATC |
|
0-L |
D05AX52 |
calcipotriol, combinations |
WHO ATC |
|
0-L |
D05B |
ANTIPSORIATICS FOR SYSTEMIC USE |
WHO ATC |
|
0-L |
D05BA |
Psoralens for systemic use |
WHO ATC |
|
0-L |
D05BA01 |
trioxysalen |
WHO ATC |
|
0-L |
D05BA02 |
methoxsalen |
WHO ATC |
|
0-L |
D05BA03 |
bergapten |
WHO ATC |
|
0-L |
D05BB |
Retinoids for treatment of psoriasis |
WHO ATC |
|
0-L |
D05BB01 |
etretinate |
WHO ATC |
|
0-L |
D05BB02 |
acitretin |
WHO ATC |
|
0-L |
D05BX |
Other antipsoriatics for systemic use |
WHO ATC |
|
0-L |
D05BX51 |
fumaric acid derivatives, combinations |
WHO ATC |
|
0-L |
D06 |
ANTIBIOTICS AND CHEMOTHERAPEUTICS FOR DERMATOLOGICAL USE |
WHO ATC |
|
0-L |
D06A |
ANTIBIOTICS FOR TOPICAL USE |
WHO ATC |
|
0-L |
D06AA |
Tetracycline and derivatives |
WHO ATC |
|
0-L |
D06AA01 |
demeclocycline |
WHO ATC |
|
0-L |
D06AA02 |
chlortetracycline |
WHO ATC |
|
0-L |
D06AA03 |
oxytetracycline |
WHO ATC |
|
0-L |
D06AA04 |
tetracycline |
WHO ATC |
|
0-L |
D06AX |
Other antibiotics for topical use |
WHO ATC |
|
0-L |
D06AX01 |
fusidic acid |
WHO ATC |
|
0-L |
D06AX02 |
chloramphenicol |
WHO ATC |
|
0-L |
D06AX04 |
neomycin |
WHO ATC |
|
0-L |
D06AX05 |
bacitracin |
WHO ATC |
|
0-L |
D06AX07 |
gentamicin |
WHO ATC |
|
0-L |
D06AX08 |
tyrothricin |
WHO ATC |
|
0-L |
D06AX09 |
mupirocin |
WHO ATC |
|
0-L |
D06AX10 |
virginiamycin |
WHO ATC |
|
0-L |
D06AX11 |
rifaximin |
WHO ATC |
|
0-L |
D06AX12 |
amikacin |
WHO ATC |
|
0-L |
D06AX13 |
retapamulin |
WHO ATC |
|
0-L |
D06B |
CHEMOTHERAPEUTICS FOR TOPICAL USE |
WHO ATC |
|
0-L |
D06BA |
Sulfonamides |
WHO ATC |
|
0-L |
D06BA01 |
silver sulfadiazine |
WHO ATC |
|
0-L |
D06BA02 |
sulfathiazole |
WHO ATC |
|
0-L |
D06BA03 |
mafenide |
WHO ATC |
|
0-L |
D06BA04 |
sulfamethizole |
WHO ATC |
|
0-L |
D06BA05 |
sulfanilamide |
WHO ATC |
|
0-L |
D06BA06 |
sulfamerazine |
WHO ATC |
|
0-L |
D06BA51 |
silver sulfadiazine, combinations |
WHO ATC |
|
0-L |
D06BB |
Antivirals |
WHO ATC |
|
0-L |
D06BB01 |
idoxuridine |
WHO ATC |
|
0-L |
D06BB02 |
tromantadine |
WHO ATC |
|
0-L |
D06BB03 |
aciclovir |
WHO ATC |
|
0-L |
D06BB04 |
podophyllotoxin |
WHO ATC |
|
0-L |
D06BB05 |
inosine |
WHO ATC |
|
0-L |
D06BB06 |
penciclovir |
WHO ATC |
|
0-L |
D06BB07 |
lysozyme |
WHO ATC |
|
0-L |
D06BB08 |
ibacitabine |
WHO ATC |
|
0-L |
D06BB09 |
edoxudine |
WHO ATC |
|
0-L |
D06BB10 |
imiquimod |
WHO ATC |
|
0-L |
D06BB11 |
docosanol |
WHO ATC |
|
0-L |
D06BB53 |
aciclovir, combinations |
WHO ATC |
|
0-L |
D06BX |
Other chemotherapeutics |
WHO ATC |
|
0-L |
D06BX01 |
metronidazole |
WHO ATC |
|
0-L |
D06C |
ANTIBIOTICS AND CHEMOTHERAPEUTICS, COMBINATIONS |
WHO ATC |
|
0-L |
D07 |
CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS |
WHO ATC |
|
0-L |
D07A |
CORTICOSTEROIDS, PLAIN |
WHO ATC |
|
0-L |
D07AA |
Corticosteroids, weak (group I) |
WHO ATC |
|
0-L |
D07AA01 |
methylprednisolone |
WHO ATC |
|
0-L |
D07AA02 |
hydrocortisone |
WHO ATC |
|
0-L |
D07AA03 |
prednisolone |
WHO ATC |
|
0-L |
D07AB |
Corticosteroids, moderately potent (group II) |
WHO ATC |
|
0-L |
D07AB01 |
clobetasone |
WHO ATC |
|
0-L |
D07AB02 |
hydrocortisone butyrate |
WHO ATC |
|
0-L |
D07AB03 |
flumetasone |
WHO ATC |
|
0-L |
D07AB04 |
fluocortin |
WHO ATC |
|
0-L |
D07AB05 |
fluperolone |
WHO ATC |
|
0-L |
D07AB06 |
fluorometholone |
WHO ATC |
|
0-L |
D07AB07 |
fluprednidene |
WHO ATC |
|
0-L |
D07AB08 |
desonide |
WHO ATC |
|
0-L |
D07AB09 |
triamcinolone |
WHO ATC |
|
0-L |
D07AB10 |
alclometasone |
WHO ATC |
|
0-L |
D07AB11 |
hydrocortisone buteprate |
WHO ATC |
|
0-L |
D07AB19 |
dexamethasone |
WHO ATC |
|
0-L |
D07AB21 |
clocortolone |
WHO ATC |
|
0-L |
D07AB30 |
combinations of corticosteroids |
WHO ATC |
|
0-L |
D07AC |
Corticosteroids, potent (group III) |
WHO ATC |
|
0-L |
D07AC01 |
betamethasone |
WHO ATC |
|
0-L |
D07AC02 |
fluclorolone |
WHO ATC |
|
0-L |
D07AC03 |
desoximetasone |
WHO ATC |
|
0-L |
D07AC04 |
fluocinolone acetonide |
WHO ATC |
|
0-L |
D07AC05 |
fluocortolone |
WHO ATC |
|
0-L |
D07AC06 |
diflucortolone |
WHO ATC |
|
0-L |
D07AC07 |
fludroxycortide |
WHO ATC |
|
0-L |
D07AC08 |
fluocinonide |
WHO ATC |
|
0-L |
D07AC09 |
budesonide |
WHO ATC |
|
0-L |
D07AC10 |
diflorasone |
WHO ATC |
|
0-L |
D07AC11 |
amcinonide |
WHO ATC |
|
0-L |
D07AC12 |
halometasone |
WHO ATC |
|
0-L |
D07AC13 |
mometasone |
WHO ATC |
|
0-L |
D07AC14 |
methylprednisolone aceponate |
WHO ATC |
|
0-L |
D07AC15 |
beclometasone |
WHO ATC |
|
0-L |
D07AC16 |
hydrocortisone aceponate |
WHO ATC |
|
0-L |
D07AC17 |
fluticasone |
WHO ATC |
|
0-L |
D07AC18 |
prednicarbate |
WHO ATC |
|
0-L |
D07AC19 |
difluprednate |
WHO ATC |
|
0-L |
D07AC21 |
ulobetasol |
WHO ATC |
|
0-L |
D07AD |
Corticosteroids, very potent (group IV) |
WHO ATC |
|
0-L |
D07AD01 |
clobetasol |
WHO ATC |
|
0-L |
D07AD02 |
halcinonide |
WHO ATC |
|
0-L |
D07B |
CORTICOSTEROIDS, COMBINATIONS WITH ANTISEPTICS |
WHO ATC |
|
0-L |
D07BA |
Corticosteroids, weak, combinations with antiseptics |
WHO ATC |
|
0-L |
D07BA01 |
prednisolone and antiseptics |
WHO ATC |
|
0-L |
D07BA04 |
hydrocortisone and antiseptics |
WHO ATC |
|
0-L |
D07BB |
Corticosteroids, moderately potent, combinations with antiseptics |
WHO ATC |
|
0-L |
D07BB01 |
flumetasone and antiseptics |
WHO ATC |
|
0-L |
D07BB02 |
desonide and antiseptics |
WHO ATC |
|
0-L |
D07BB03 |
triamcinolone and antiseptics |
WHO ATC |
|
0-L |
D07BB04 |
hydrocortisone butyrate and antiseptics |
WHO ATC |
|
0-L |
D07BC |
Corticosteroids, potent, combinations with antiseptics |
WHO ATC |
|
0-L |
D07BC01 |
betamethasone and antiseptics |
WHO ATC |
|
0-L |
D07BC02 |
fluocinolone acetonide and antiseptics |
WHO ATC |
|
0-L |
D07BC03 |
fluocortolone and antiseptics |
WHO ATC |
|
0-L |
D07BC04 |
diflucortolone and antiseptics |
WHO ATC |
|
0-L |
D07BD |
Corticosteroids, very potent, combinations with antiseptics |
WHO ATC |
|
0-L |
D07C |
CORTICOSTEROIDS, COMBINATIONS WITH ANTIBIOTICS |
WHO ATC |
|
0-L |
D07CA |
Corticosteroids, weak, combinations with antibiotics |
WHO ATC |
|
0-L |
D07CA01 |
hydrocortisone and antibiotics |
WHO ATC |
|
0-L |
D07CA02 |
methylprednisolone and antibiotics |
WHO ATC |
|
0-L |
D07CA03 |
prednisolone and antibiotics |
WHO ATC |
|
0-L |
D07CB |
Corticosteroids, moderately potent, combinations with antibiotics |
WHO ATC |
|
0-L |
D07CB01 |
triamcinolone and antibiotics |
WHO ATC |
|
0-L |
D07CB02 |
fluprednidene and antibiotics |
WHO ATC |
|
0-L |
D07CB03 |
fluorometholone and antibiotics |
WHO ATC |
|
0-L |
D07CB04 |
dexamethasone and antibiotics |
WHO ATC |
|
0-L |
D07CB05 |
flumetasone and antibiotics |
WHO ATC |
|
0-L |
D07CC |
Corticosteroids, potent, combinations with antibiotics |
WHO ATC |
|
0-L |
D07CC01 |
betamethasone and antibiotics |
WHO ATC |
|
0-L |
D07CC02 |
fluocinolone acetonide and antibiotics |
WHO ATC |
|
0-L |
D07CC03 |
fludroxycortide and antibiotics |
WHO ATC |
|
0-L |
D07CC04 |
beclometasone and antibiotics |
WHO ATC |
|
0-L |
D07CC05 |
fluocinonide and antibiotics |
WHO ATC |
|
0-L |
D07CC06 |
fluocortolone and antibiotics |
WHO ATC |
|
0-L |
D07CD |
Corticosteroids, very potent, combinations with antibiotics |
WHO ATC |
|
0-L |
D07CD01 |
clobetasol and antibiotics |
WHO ATC |
|
0-L |
D07X |
CORTICOSTEROIDS, OTHER COMBINATIONS |
WHO ATC |
|
0-L |
D07XA |
Corticosteroids, weak, other combinations |
WHO ATC |
|
0-L |
D07XA01 |
hydrocortisone |
WHO ATC |
|
0-L |
D07XA02 |
prednisolone |
WHO ATC |
|
0-L |
D07XB |
Corticosteroids, moderately potent, other combinations |
WHO ATC |
|
0-L |
D07XB01 |
flumetasone |
WHO ATC |
|
0-L |
D07XB02 |
triamcinolone |
WHO ATC |
|
0-L |
D07XB03 |
fluprednidene |
WHO ATC |
|
0-L |
D07XB04 |
fluorometholone |
WHO ATC |
|
0-L |
D07XB05 |
dexamethasone |
WHO ATC |
|
0-L |
D07XB30 |
combinations of corticosteroids |
WHO ATC |
|
0-L |
D07XC |
Corticosteroids, potent, other combinations |
WHO ATC |
|
0-L |
D07XC01 |
betamethasone |
WHO ATC |
|
0-L |
D07XC02 |
desoximetasone |
WHO ATC |
|
0-L |
D07XC03 |
mometasone |
WHO ATC |
|
0-L |
D07XC04 |
diflucortolone |
WHO ATC |
|
0-L |
D07XD |
Corticosteroids, very potent, other combinations |
WHO ATC |
|
0-L |
D08 |
ANTISEPTICS AND DISINFECTANTS |
WHO ATC |
|
0-L |
D08A |
ANTISEPTICS AND DISINFECTANTS |
WHO ATC |
|
0-L |
D08AA |
Acridine derivatives |
WHO ATC |
|
0-L |
D08AA01 |
ethacridine lactate |
WHO ATC |
|
0-L |
D08AA02 |
aminoacridine |
WHO ATC |
|
0-L |
D08AA03 |
euflavine |
WHO ATC |
|
0-L |
D08AB |
Aluminium agents |
WHO ATC |
|
0-L |
D08AC |
Biguanides and amidines |
WHO ATC |
|
0-L |
D08AC01 |
dibrompropamidine |
WHO ATC |
|
0-L |
D08AC02 |
chlorhexidine |
WHO ATC |
|
0-L |
D08AC03 |
propamidine |
WHO ATC |
|
0-L |
D08AC04 |
hexamidine |
WHO ATC |
|
0-L |
D08AC05 |
polihexanide |
WHO ATC |
|
0-L |
D08AC52 |
chlorhexidine, combinations |
WHO ATC |
|
0-L |
D08AD |
Boric acid products |
WHO ATC |
|
0-L |
D08AE |
Phenol and derivatives |
WHO ATC |
|
0-L |
D08AE01 |
hexachlorophene |
WHO ATC |
|
0-L |
D08AE02 |
policresulen |
WHO ATC |
|
0-L |
D08AE03 |
phenol |
WHO ATC |
|
0-L |
D08AE04 |
triclosan |
WHO ATC |
|
0-L |
D08AE05 |
chloroxylenol |
WHO ATC |
|
0-L |
D08AE06 |
biphenylol |
WHO ATC |
|
0-L |
D08AF |
Nitrofuran derivatives |
WHO ATC |
|
0-L |
D08AF01 |
nitrofural |
WHO ATC |
|
0-L |
D08AG |
Iodine products |
WHO ATC |
|
0-L |
D08AG01 |
iodine/octylphenoxypolyglycolether |
WHO ATC |
|
0-L |
D08AG02 |
povidone-iodine |
WHO ATC |
|
0-L |
D08AG03 |
iodine |
WHO ATC |
|
0-L |
D08AG04 |
diiodohydroxypropane |
WHO ATC |
|
0-L |
D08AH |
Quinoline derivatives |
WHO ATC |
|
0-L |
D08AH01 |
dequalinium |
WHO ATC |
|
0-L |
D08AH02 |
chlorquinaldol |
WHO ATC |
|
0-L |
D08AH03 |
oxyquinoline |
WHO ATC |
|
0-L |
D08AH30 |
clioquinol |
WHO ATC |
|
0-L |
D08AJ |
Quaternary ammonium compounds |
WHO ATC |
|
0-L |
D08AJ01 |
benzalkonium |
WHO ATC |
|
0-L |
D08AJ02 |
cetrimonium |
WHO ATC |
|
0-L |
D08AJ03 |
cetylpyridinium |
WHO ATC |
|
0-L |
D08AJ04 |
cetrimide |
WHO ATC |
|
0-L |
D08AJ05 |
benzoxonium chloride |
WHO ATC |
|
0-L |
D08AJ06 |
didecyldimethylammonium chloride |
WHO ATC |
|
0-L |
D08AJ08 |
benzethonium chloride |
WHO ATC |
|
0-L |
D08AJ57 |
octenidine, combinations |
WHO ATC |
|
0-L |
D08AJ58 |
benzethonium chloride, combinations |
WHO ATC |
|
0-L |
D08AJ59 |
dodeclonium bromide, combinations |
WHO ATC |
|
0-L |
D08AK |
Mercurial products |
WHO ATC |
|
0-L |
D08AK01 |
mercuric amidochloride |
WHO ATC |
|
0-L |
D08AK02 |
phenylmercuric borate |
WHO ATC |
|
0-L |
D08AK03 |
mercuric chloride |
WHO ATC |
|